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ABSTRACT
A literature survey has shown that some simple peptides and their 
derivatives and also some amino acid derivatives have pharmacological 
activities of interest.
The thesis describes the preparation and characterisation of amino 
acid and thence of peptide derivatives of Aspirin, acetylsalicylic 
acid, and then of Alclofenac, 4-allyloxy-3-chlorophenylacetic. acid. 
Acetylsalicyloyl-(DL)-alanine, and some amino acid and dipeptide 
derivatives (and one tripeptide derivative) of Alclofenac were 
prepared.
The compounds have been submitted for pharmacological testing.
The results obtained todate indicate that Alclofenac-(DL)-alanine 
methyl ester and Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester 
are bioactive compounds. They inhibit the release of histamine 
from rat peritoneal mast cells in vitro. Further, Alclofenac- 
glycine and its hydrogenated form, 3-chloro-4-n-propoxyphenylacetyl- 
glycine, show as much anti-inflammatory activity in vivo as does 
Alclofenac.
Derivatives are named arbifertxf\\^as, e.g. Alclofenac-glycine 
etc inhere the first part of such composite names refers 
strictly to the acyl radical derived from the acid, Alclofenac.
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Drugs have pharmacological effects in vivo. No two drugs are 
identical? however, they can be classified, since many have
1qualitatively similar effects.
Certain drugs are known to be anti-inflammatory agents, and have 
been proposed for the relief of rheumatism and other disorders 
involving inflammation . However, some of them give rise to 
toxicity problems or are not very effective. Two anti-inflammatory 
drugs that have been and are used are Aspirin and Alclofenac.
Although, salicylic acid, o-hydroxybenzoic acid, had been known
for a long time to have pharmacologically useful properties, it
was not suited for systemic use, because of its irritant nature.
The acetylated form of this acid, Aspirin, acetylsalicylic acid,
2was then introduced into medicine in 1899.
As an anti-inflammatory drug it has found good uses in medicine
over the years. However, it has undesirable side effects. In
the stomach it causes ulcerative lesions, which are believed to
3be due to its free carboxyl group. Substitution on the carboxyl
group may help to change its gastrotoxicity. However, this has
to be achieved to such a degree that effective Aspirin-like drug
activity is also retained. This has recently been tried on
salicylic acid itself, some a-amino acid derivatives of salicylic
acid have been prepared-but none have been found to have anti-
4inflammatory activity. Attempts at coupling simple peptides
and amino acids (or their derivatives) onto Aspirin in the hope 
of making the drug more potent but showing less gastrotoxicity 
than Aspirin still continue.
Alcofenac, 4-allyloxy-3-chlorophenylacetic acid, originated from 
the laboratory of Professor Buu-Hoi, at the Radium Institute of 
the University of Paris in 1966? It was later developed by him 
and by chemists at the Continental Pharma in Belgium.0 They 
studied a whole series of such arylacetic acids of the general 
formula,
(Where X = 0, or CH2;Y = halogen, or H;R = alkyl or H; and R^ = 
alkyl or alkenyl). Over a hundred such compounds were tested 
for further study, one of which was 4-allyloxy-3-chlorophenylacetic 
acid, Alclofenac.
The assessment of Alclofenac in the well known experiments for
Like Aspirin, being a non-sterdidal anti-inflammatory drug, it 
found medicinal uses and was recommended for use in the treatment 
of chronic rheumatoid arthritis and other disorders involving 
inflammation. Unlike Aspirin it caused insignificant amounts
Cl
analgesic properties revealed that it had considerable potency.7
Qof gastric damage. This was a decisive factor which prompted
consideration of Alclofenac for use as a drug.
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Mean daily blood loss in volunteers during control period and 
after taking 3g. alclofenac or 3.6g soluble aspirin daily
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binding sites, by an anti-inflammatory drug such Alclofenac as an
indication of its activity in vivo. When Alclofenac is assessed
in this way it shows up extremely well with other anti-inflammatory
10 11agents, being as effective as D-Penicillamine, Indomeand
12more effective than Aspirin. However, in the tablet form rather than
13the capsule form, it causes in some patients skin rashes and because
of this side effect Alclofenac has recently been withdrawn from the 
14market.
The alteration of the molecular structure of a particular drug 
molecule, or, alternatively, attachment of another biologically 
active molecule, may help to increase its potency or decrease its 
toxicity. The latter approach produces interesting results and 
is often the more preferred.
Amongst the biologically active molecules are peptides. Some 
simple peptides and derivatives have been found to show useful 
pharmacological properties in vivo.
9Aylward has described the liberation of L-tryptophan, from its
For example:
1) Peptides of the general formula,
P., R0
I 1 I2CH CH
! 2 i 2I'V./sj -C-C0-NH-C-C00H 
A H H
15were found to be anti-inflammatory agents. R2
are the same or different, each is either phenyl- or 
3-indolyl; each of the amino acids may have either the D- 
or L-stereoisomeric form).
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2) The dipeptide phenylalany 1-phenylalanine, has also been
16reported by West to show anti-inflammatory properties 
in vivo.
3) Peptide derivatives of the general formula,
1;H—CH (NH. R. ) CO -Me t-Asp-Phe-NH,2 i
were found to be useful in the treatment of gastric 
ulcers.
(R=2-°2N-c6HrS-f 2, 4- (02N) -C6H3S-;
■rLh, (Me)jC-O-CO-Gly, (Me)*C-O-CO-p-Ala, B-Ala, Gly)
4) Peptide derivatives of the general formula,
0
B -P—P—P^r-NH-N-C-R,4 3 2 j 2
were found to be useful in the treatment of pancreatitis
18and rheumatoid arthritis.
(B = C^ alkanoyl (such as acetyl),
jt-butyloxycarbonyl or carbobenzoxy,
P^ - Ala, or Pro, P^ = Ala, P^ = Pro or Leu
R^ = C^_5 alkyl (such as methyl) and,
R0 = C, _ alkoxy (such as ethoxy),2 l-o
benzyloxy or amino (C, _) alkoxy (such as1—5
5-amino-amy.loxy) . 
or R^ is,
-NH-CH-C-O-R .
R 43
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alkyl (such as ethyl or benzyl) .
Not only simple peptides and their derivatives but also certain 
amino acid derivatives show useful pharmacological properties 
in vivo.
For example,
1) Phenylglycine and phenylglycine heptyl ester were
found to show useful anti-inflammatory activities 
19 20in vivo. ' The latter has also been suggested to 
have certain uses in the treatment of some allergic 
diseases.
2) The cysteine derivative of the formula,
Where R^ = alkyl (such as methyl) , benzyl, and R4 = 5
CO-NH-CH (C02Na) CHrpCH—SNa
22was found to have bronchomucolytic properties.
,ch2~ch(nh2)co2h
Substituted alanines of the general formula
d i
and
co2h
(II)
and their pharmaceutically acceptable salts were found
24to be anti-hypertensive agents.
(R = H,OH)
3,3-Diphenylpropylamides of L-amino acids of the general 
formula,
H-X-NH-CH—CH™CH (Ph) .
were found to be potential vasodilators of low toxicity, 
(X = Val, Leu, Glu-OMe) .
25
N-(4-Pyrrolidino-2—butynyl)-L-proglutamide and its 
(DL)-isomer of the formula:-
were found to be anti-Parkinsonian agents.26
CH2-CH(NH2)
It is of interest, therefore, to try to attach amino acids (or 
their derivatives), or simple peptides to drugs in the hope of 
preparing materials of pharmacological importance. Chemical 
Abstracts, 89 , reveals the extent of such interest; in that 
volume there were some thirty-eight papers devoted to such topics. 
Numerous such derivatives have been prepared and their 
pharmacological activities studied. Many have been found to have 
some beneficial pharmacological effects and perhaps some may find 
good uses in medicine.
The object of this research programme has been to try to prepare 
materials of pharmacological interest; in particular those with 
anti-inflammatory activity. Since the dipeptide phenylalanyl- 
phenylalanine, has been reported recently by West, to have 
anti-inflammatory properties, perhaps, the attachment of such an 
entity on to an anti-inflammatory drug may produce one which is 
itself more potent in this respect. Furthermore, some novel, 
useful, pharmacological activity may appear and perhaps any 
side effects a drug has may be masked if simple biologically 
active peptides or amino acids (or their derivatives) are coupled 
to it.
A systematic variation in the structure of a drug molecule will 
often produce a systematic variation in its pharmacological 
properties. It may therefore be of interest to try to prepare 
first mono-, di- and tri-peptide derivatives of a particular 
drug. Then, perhaps having obtained pharmacological results of 
a few such derivatives to try to correlate them. It is hoped 
that this will be a guide to the establishment of a molecular
- 10 -
structure-in vivo relationship. The synthesis and structure-activity
relationships of a variety of aromatic and heterocyclic sulfonyl-amino
27-31acids have been reported in a series of papers by E 1-Nagger et al.
The sulfonamides were compounds whose pharmacological effects and
32usefulness were predicted.
It. was proposed to prepare derivatives of Aspirin and of Alclofenac
and to have these products tested for pharmacological activity.
Furthermore, Alclofenac has some toxic properties believed to be
33associated with the unsaturated side chain. The preparation of 
the hydrogenated forms of amino acid derivatives of Alclofenac may 
also be of interest.
PHARMACOLOGICAL TESTING
Preliminary pharmacological tests were carried out at the USV 
Pharmaceutical Corporation, Tuckahoe, New York, 10707. (They 
are reported here as in USV Protocols).
1) Test No. 400 - Antihypertensive:
The purpose of this test is to find compounds which 
will be of xose in the treatment of human hypertension.
Test compounds are injected intraperitoneally into 
hypertensive rats, changes in the blood pressures 
are recorded and compared with those following the 
injection of vehicle only. If the test compound 
causes a greater fall in blood pressure than the 
vehicle, and if the drug does not appear to have 
severe side effects, the compound is of further 
interest as an anti-hypertensive.
2) Test No. 475 - Cardiac Performance:
The purpose of this test is to find compounds which 
will alter the contractile state of isolated heart 
muscle.
The guinea pig or cat heart muscle preparations are 
equilibrated for approximately one hour at 30°C at pH 7.4 
in a modified Krebs-Ringer solution. They are stimulated 
by square-wave pulses at a constant frequency, quick
- 12 -
muscle length is found. The resting tension of the
spontaneously beating muscle preparation is set at
a level which will provide for suitable readings.
Muscle lengths are kept constant throughout the
experiment. Following the one hour equilibration
period, three fast control records are obtained at
15 minute intervals. The isolated muscle preparation
-Ais then exposed to cumulative additions up to 10 M 
of the test compound. High speed readings are 
recorded immediately upon attainment of a steady state.
Changes in the contractile state of the heart muscle 
caused by the test compound are determined. A 
positive inotropic effect is of particular interest.
3) Test No. 701A - PDE (Dog Heart) (In vitro Assay for 
Effectors of Cyclic Nucleotide - Phosphodiesterase):
The purpose of the test is to find compounds whichA
would act as effectors of the enzyme nucleotide-phosphodiesterase 
(cNuc-PDEase). This enzyme hydrolyses the cyclic nucleotides 
particularly adenosine-3',5'-monophosphate (cyclic AMP) and 
guanosine-31, 51-monophosphate (cyclic GMP) to their corresponding 
51-nucleotides.
The test procedure utilizes a radioactively labelled 
3substrate ( H-cyclic nucleotide) and a non-rate limiting 
amount of 5'-nucleotidase to convert the 5'-nucleotide 
product of cNuc-PDEase to the corresponding nucleoside.
length-tension curves are obtained and the optimal
- 13 -
The charged, unhydrolysed, substrate is chromatographically 
separated and quantified using a liquid scintillation 
counter.
The test is done in the presence and absence of the test 
compound and the changes in the hydrolytic reaction are 
noted. If the compound stimulates (cNuc-PDEase) activity 
it is of further interest.
4) Test No. 702 - Lung Mast Cell (Guinea Pig Lung Histamine 
Release Assay):
The purpose of this test is to find compounds which would 
inhibit the release of histamine and may be of use 
in allergic reactions.
Guinea pig lung slices are passively sensitized in vitro 
*with guinea pig serum. Spontaneous histamine release.(SR)
(in the absence of antigen) and anaphylactically induced 
histamine release (in the presence of the antigen) from 
these passively sensitized lung slices are measured, after 
a fifteen minute incubation, fluorometrically. Net 
antigen-induced histamine, (AIR) , is obtained by subtracting 
SR from that in the presence of the antigen. The effect of 
a test compound on (SR) and (AIR) is determined following a 
five minute pre-incubation of sensitized lung slices with 
the test compound.
The compound activity is expressed as a percentage 
inhibition of the net antigen-induced histamine release
- 14 -
concentration of the compound required for 50%
inhibition of (AIR) , (1,-rf is determined.oU
5) Test No. 703 - Rat Mast Cell (In Vitro Release
of Histamine from Rat peritoneal Mast Cells):
The test is the same as test, No. 702 except this time 
mast cells from the rat peritoneum are used.
6) Test No. 704 - ACEI (Test for the inhibitions of
Angiotensin - Converting Enzyme Activity):
The purpose of this test is to find conpounds which 
will inhibit the activity of Angiotensin-converting 
enzyme (ACE). ACE is an enzyme that catalyses the 
hydrolyses of the tripeptide, hippuryl-histidyl-leucine 
or Angiotensin I, (HHL), which has no biological activity.
The products of the reaction are hippuric acid and 
histidyl-leucine or Angiotensin II which is a potent 
vasoconstrictor.
The test involves incubating HHL with ACE at 37°C.
The enzyme reaction is stopped by adding hydrochloric 
acid. Hippuric acid is isolated by extracting with 
ethyl acetate. After evaporating off the solvent, 
the residue containing hippuric acid is dissolved 
in water. The concentration of hippuric acid is 
determined spectrophotometrically by comparing the 
absorbance of the solution at 228nm with the absorbance 
of known concentrations of the pure compound.
(AIR). In the case of an active compound the
- 15 -
The enzyme activity is measured by the amount of 
hippuric acid formed in the presence and the absence 
of the test compound. If the compound inhibits the 
activity of ACE the compound is of further interest 
as an antihypertensive. Test compounds are rated 
in terms of their ability to decrease the specific 
activity of ACE. The specific activity of ACE is 
expressed as nanomoles of hippuric formed/min/mg. 
of the tripeptide.
7) Test No. 705 - IgEBA (Binding Assay for Immunoglobin E): 
The purpose of this test is to find conpounds which may 
be of use in certain allergic diseases. Antibodies of 
IgE class bind to specific receptors on the surface of 
the target cells. The receptors are able to transduce 
the antigen's signal and initiate a series of 
exocytolytic reactions. This mechanism has importance 
in allergic disease states.
The test involves quantification of the extent of 
125binding I-labelled IgE antibody to its specific 
receptors on rat peritoneal mast cells (RMC) in the 
presence and the absence of the test compound. RMC
A 4 Arare incubated at 37 C with I-labelled IgE in
borosilicate glass tubes. Then 75yl. is withdrawn
from each and cell bound I-IgE is separated from the 
125soluble I-IgE by centrifugation.
.125The amount of ‘ I-IgE bound to RMC is then quantified 
with a -spectrometer. Test compounds which limit the
- 16 -
binding of I-IgE to RMC by competing for receptor 
sites on RMC are of further interest.
8) Test No 706 - Cyclase (Adenylate) Dog Heart:
The purpose of this test is to find compounds which 
would affect the activity of the enzyme Adenylyl-cyclase.
This enzyme converts adenosine- t 51-triphosphate 
(ATP) to adenosine-5’-monophosphate (AMP). The tissue 
source of this enzyme is dog heart ventricular muscle 
for the test purposes.
The test involves measuring the enzyme activity in the
presence and the absence of the test compound at 37°C
32 32 using a- P-ATP as the substrate. The product P“cyclic
AMP is separated chromatographically and the amount of 
32v p-cyclic AMP formed is measured with a T -*■ •
Test compounds which activate the adenylyl-cyclase are 
of further interest.
9) Test No 707 - Kinase (CAMP) Bovine Heart:
The purpose of this test is to find compounds wnich
(would affect the activity of cyclic AMP-dependent 
(CAMP) protein kinases and their modulators. This 
class of enzymes, whose activity is stimulated by 
cyclic AMP, catalyses the transfer of -phosphate of 
ATP to cellular proteins. The tissue source of this 
enzyme is bovine heart for test purposes.
- 17 -
presence and absence of (CAMP) with test compound
32using P-labelled ATP as substrate and cellular
32protein histone. The transfer of ft- P from
32radioactive substrate ft- P-ATP to cellular protein 
32histone to form a P-histone product occurs.
32The product P-histone is isolated by paper 
chromatography and its amount measured using a 
ft-spectrometer.
If the compound is more effective than (CAMP) in 
activating kinases then it is of further interest.
10) Test No 708 - Lipase (Triacylglycerol) Assay:
The purpose of this test is to find compounds which 
are antilipolytic agents, that will decrease the 
cardiac lipase activity. As a consequence of sudden 
coronary occlusion there is a rapid increase in free 
fatty acids (FFA) due to increased lipolysis brought 
about by the enzyme lipase in the heart tissue. FFA 
accumulation stops the metabolic processes, glycolysis, 
and ADP-ATP exchange. This plays a major role in 
determining the extent of tissue damage during a 
heart attack. Antilipolytic agents which inhibit 
cardiac lipase activity are necessary to prevent such 
tissue damage. The tissue source of this enzyme for the 
test purposes is dog heart muscle.
The test involves measuring enzyme activity in the
- 18 -
The test involves measuring cardiac lipase activity 
2using a ( H)-triolein substrate at 37 C in the presence 
and the absence of the test compound. The reaction is 
stopped by adding sulphuric acid and the product,
3radiolabelled FFA, ( H;FFA, is extracted. The amount
3of ( H)FFA formed is measured by liquid scintillation 
counting.
If the test compound inhibits the activity of the 
enzyme cardiac lipase then it is of further interest 
as an antilipolytic agent.
- 19 -
(B) The anti-inflammatory tests were carried out at the Huntingdon 
Research Centre, Huntingdon, Cambs, PE 18 6ES„
(Theo test procedure is reported here as in Huntingdon Research 
Centre Protocol);. .
The test involves measuring the inhibition of an experimentally- 
induced paw oedema in rats.
Procedure:
The rats are fasted 18 hours prior to dosing, but water is made 
available to them. Test compounds are then administered in 
aqueous 1% tragacanth, at a dose volume of 25ml/kg. One group 
of rats is given vehicle only at the same dose volume. Forty 
five minutes later, all rats are given a subplantar injection of 
O.lmlo of a 1% solution of carrageenin in 0.9% saline in the left 
hind paw. The volume of this paw is measured before and after 
the carrageenin injection using a volume differential meter 
designed by Ugo Basile.
  Anti-inflammatory activity is measured as the percentage
inhibition of paw oedema in the drug treated animals compared 
to the controls.
- 20 -
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THE PREPARATION OF SIMPLE PEPTIDES:
A .peptide is a compound in which amino acids are covalently linked 
together through secondary amide or peptide bonds (-C0-NH-). The 
term protein, derived from the Greek word proteios ('primary'), was 
coined before anything was known about the chemical structures of 
these naturally occurring macromolecules. It is conventional to use 
this term for large molecules and to use the term peptide for 
molecules which are built up from only a small number of ami nn acid 
residues. The molecular sizes of the natural peptides and proteins 
cover a wide range. It is debatable, however, whether the
adrenocorticotrophic hormone, which is built up of thirty nine
34 .ammo acid residuesf is a peptide or a polypeptide. The
concept of peptides and polypeptides was put forward by Fischer 
35in 1906.
A peptide synthesis is characterised by the formation of an amide 
bond between the carboxyl group of one amino acid and the amino 
group of a second amino acid;
1*6#/ I1
BL
H2N-CH-C00H + H2N-CH-C00H
f i
-H20
H2N-CH-C0-NH-CH-C00H
Since the amide bond formation from the carboxyl group and an amino 
group does not occur spontaneously, one of these two groups has to be 
converted into a form wnich is reactive (i.e. activated).
A peptide chain may be b u ilt  up from either the N-terminus or the 
C-terminus, but the lite ra tu re  of the subject indicates a strong 
preference for the la tte r approach.
9
6(+)
R CH — C X
I 1m2 o 6 (-)
X = Activating group
(negative substituent)
Carboxyl activation (in general) is  achieved by the introduction 
of a negative substituent, X. The negative inductive effect 
decreases the electron density on the carbonyl carbon atom. The 
resulting e lectrophilic centre provides the driving force for the 
peptide bond-forming reaction, allowing the nucleophilic amino 
group to attack more easily. However, peptide synthesis cannot 
usually proceed with free amino acids, since the free amino acids 
exist as zwitterions of d iffe ren t mesomeric forms.
- 21 -
•O- <“ > •• (~) n-H,iXR H. XR , .Os H, R a0*n+)i /  K+)i (+ r  )(+)» //
■N— CH— Cs H--- N-—CH C' H--- N CH— C
I *0; » >5: 1 S8-H •• H , H »•
(mesomeric forms)
Protection of one of the functional groups is  a prerequisite in 
peptide synthesis, since i t  deprives the amino acid of its  a b ility  
to form th is inner sa lt, zwitterion.
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The general scheme for a dipeptide synthesis is as given below; 
(involving in this case, activation at the Oterminus);
(i) Protection;
Z-NH-CH-COOH; E^N-CH-COOY
Z = amino protecting group 
Y = carboxyl protecting group
(ii) Activation;
11Z-NH-CH-COOH + X"1 
Z-NH
X = electronegative substituent
1]i i-CH-COX + OH*"1
(iii) Interaction of the activated form with the 
protected form to give a protected peptide;
R< ro11 |2
Z-NH-CH-COX + H2N-CH-C00Y
-HX „
|1 ^2 
Z-NH-CH-CO-NH-CH-COOY
(iv) The final step is the removal of the protecting 
groups Z and Y to give the free dipeptide;
^2
Z-NH-CH-CO-NH-CH-COOY
1 j.H2N-CH-C0-NH-CH-C00H
(In this research programme stepwise synthesis is 
involving the coupling of one amino acid at a time
23 -
was attempted firstly on Aspirin, and secondly on 
Alclofenac. The peptide chain was built at the 
C-terminus. No N-protection was necessary since 
both Alclofenac and Aspirin served as N-protectors;, 
carboxyl protection by salt formation or by 
esterification was used.)
Carboxyl protection by salt formation:
This is achieved readily by adding a mole of an amino acid to a 
mole of aqueous sodium hydroxide to give an aqueous solution 
of the salt.
Although this amino acid salt can be isolated by evaporation of 
the solvent the coupling reaction requires it to be in solution. 
These salts are normally soluble in water. The coupling reaction 
has therefore to proceed under aqueous conditions and the 
hydrolysis of the activated compound is likely to occur.
The difficulties can be sometimes overcome by working in an
36 37aqueous-organic solvent mixture ' (e.g. retrahydrofuran/water;
and by maintaining a fairly low temperature under not too basic
38,39conditions, by maintaining a constant pH (about 7.0-9.5).
-CH-C00( } + NaOH > (I^-CH-C00) ("}Na(+) + 0H(_)
(Zwi tterion) (Nucleophile)
The free acid for the next coupling step is obtained by acid 
treatment at the completion of the peptide synthesis.
- 24 -
(R-CO-NH-CH-COOj^Na9 + HC1
• IR-CO-NH-CH-COOH + NaCl.
The isolation of the reaction product is difficult since the 
starting carboxyl component and the end product are present as 
acids.
The mixed alkyl carbonic anhydride method and the carbonyldiimidazole 
method have been used with salts as coupling components.40'4*
Carboxyl protection by esterification?
It is achieved by passing dry hydrogen chloride gas into a 
suspension of the amino acid in a dry alcohol e.g. methanol, to 
give the amino ester hydrochloride.
*H2N-CH-COOH + CHgOH + HC1
(+) ? (-)(H'n-CH-CCLCH ) c i V '3 2 3
(Amino acid ester hydrochloride)
This ammonium form of the ester is not capable of taking part in
the peptide bond-forming reaction. Free esters are generated
in situ by adding an equivalent amount of a base such as
triethylamine .
R
(+) ^(h3n-ch-co2ch3)c i > + Et3N
N-CH-C02CH3 + (Et3N(+,H)Cl"
H2 R
(nucleophile) (triethylammonium. chloride)
(amino ester)
- 25 -
They may also be obtained by .adding aqueous alkali and then 
extracting into an organic solvent, e.g. ether (as in the azide 
method of coupling see p. 74 ) .
It is therefore better to store them as salts and generate the free 
esters at the time of coupling.
H N-CH-C02CH 
(free amino ester)
- 2CH3OH
(dike topipe razine)
The advantages of protection by esterification;
(i) Amino acids are poorly soluble in organic solvents 
required as the medium of coupling for the majority 
of the coupling reactions; esterification at the 
C-terrain us renders them soluble.
(ii) Since the starting carboxyl component is an acid 
and the final product an ester product separation 
is easier.
Amino acid esters with short side chains form dike top iperazines42
C,X ■'nR-HC
(iii) The protecting groups are easily removable in most 
cases without cleavage of the peptide bond.
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The methods used in th is  research programme are those involving 
synthesis by activation of the carboxyl group.
«•
The following methods were used;
Formation of the peptide bond;
(i)
( i i)
( i i i )
(iv)
Mixed anhydride method, (MCA). 
N,N-Dicyclohexylcarbodiimide method, (DCC).
Azide method (A).
Activated ester method, (p-nitrophenyl ester was 
used), (ONP).
(v) N,N-carbonyldiimidazole method, (CDI).
Activated intermediates of the coupling methods (i) to (v)
(i)
0 0 
R—C C R
1 \ / v 2o o
Mixed anhydride 
(MCA Method). (DCC Method)
//R-C ,\ C+H-1 N=N=N
( i i i )  Azide (A Method). (iv) p-nitrophenyl ester
(ONP Method).
(vg Acylimidazole 
(CDI Method)
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(i) Mixed anhydride method: (MCA)
The method was developed by Boisscnnas and later 
44by Vaughan . The anhydrides are outstanding 
having the advantage that their aminolytic 
cleavage yields, in addition to the peptide, 
carbon dioxide and an alcohol which can both 
easily be removed, giving a clean product.
Activation:
43
R-COOH + ClC02Et ---
(ethyl chloro 
formate)
The mixed anhydrides are prepared by the action
of an alkyl chloroformate (e.g. ethyl chloroformate)
on an N-protected amino acid at low temperatures in
40an organic solvent (e.g. tetrahydrofuran). At
aminolysis the amino acid component is usually added
40,44 45as a salt or as an ester; usually the
temperature must not rise above 0°C.
Aminolysis:
0 1
*-<? h2n-r
X0 , — > R-CO-NH-R + C0„+ EtOHEt 0 C (.amxno component) (peptide) 2
'b
(mixed anhydride)
R-<^
Et-O-C\'0
(mixed anhydride)
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intermediate at the wrong anhydride bond are
greater in an aqueous alkaline solution than
46-48m a pure organic phase.
The chances for the opening of the active
( i i)  N/Nkpicyclohexylcarbodiimide method: (DCC)
This method for the formation of peptide bonds
49was introduced by Sheehan and Hess. Its
50mechanism is  not fu lly  understood. Khorana 
has suggested an activation of the carboxyl group 
in itia te d  by the addition of its  proton to the 
double bond of the carbodiimide to form an 
0-acylisourea.
Activiation:
i 2
(N,N-dicyclohexylcarbodiimide)
(£-acylisourea)
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The O-acylisourea may react in two ways? 0_-N 
migration (reaction (a) see p. 30 ) and the
formation of an N-acylurea is one alternative 
if there are no further protons available.
In presence of further acid a second addition
of a proton takes place (reaction (b) and the
0+N migration is prevented. Stabilisation by '
the way of formation of a symmetrical anhydride
and a disubstituted area is achieved. The
formation of the peptide bonds according to- 
50Khorana may proceed from the symmetrical
anhydride (reaction (c)) or the N-acylurea
51(reaction (d)). Diehl , however reported that 
N-acylurea is  not an activated compound.
52Schussler and Zahn have been able to prove 
that reactivity of symmetrical anhydrides of 
carbobenzoxy-amino acids and carbobenzoxy-peptides 
is sufficient for peptide coupling reactions 
under conditions used in the carbodiimide method.
Direct attack of the amino component on the reactive 
intermediate, O^acylisourea reaction (e) to form
peptide bonds is  also possible.
(am
ino
 
co
m
po
ne
nt
)
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Aminolysis:
The advantage of th is method of coupling is  that
ithe by-product N,N~dicyclohexylurea, (DCU) , is  
insoluble in  most organic solvents and can be 
filte re d  of f .  However, sometimes the undesired 
formation of an N-acylurea occurs and its  
separation from the product may be d if f ic u lt .  This 
method of coupling was often used successfully 
in th is research programme.
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( i i i )  The Azide:method: (A)
This method of coupling was reported by Curtius
53-60 A .m a series of papers. Acyl azides are
formed by the action of nitrous acid on an acid 
hydrazide. The la tte r compounds are obtained 
by hydrazinolysis of methyl or ethyl esters of 
amino acids. The reaction is normally carried 
out by standing the alcoholic solution of the 
ester with hydrazine hydrate.
Activation
*0R-crf
OMe NHr NH2
sR-C
'l-JH-NH,
(amino ester)
R-Cs f-
(azide)
(hydrazide)
HONO
R-C*0\ N-NH
NO
Azides of protected amino acids or peptides 
condense with the free amino group of a 
C-protected amino acid, with the elimination 
of hydrazoic acid.
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Aminolysis
?i
Z-NH-CH-CON3 + H2N-CH-C02Y
(azide) (C-protected amino acid)
R
Z-NH“CH-C0-NH-CH-C02Y + hn3 
(protected dipeptide) (hydrazoic acid)
The instability of the azides leads to a number 
of side reactions the most significant being a
decomposition of the azide and a rearrangement
to give an isocyanate. Then further reaction
with the added amino-component makes possible
the formation of a urea derivative. This side
54 59reaction was observed by Curtius. '
61Curtius degradation. This involves the
R1-c-n~nLn'
0
H2N-R2 + R—N=C=0
(amino component) (isocyanate)
r 1-nh-co-nh-r2
(urea derivative)
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The problem was investigated by Harris and 
62Fruton who recommended use of low temperatures 
to minimise th is tendency.
The formation of an acid amide is  another side
reaction frequently encountered in th is coupling
6 3method. Prelog and Wieland f i r s t  reported this 
side reaction and la te r i t  was confirmed by many 
authors.64' 65 Honzel and Rudinger66 studied 
amide bond formation in the case of 
carbobenzoxy-S-benzylcysteine hydrazide? high 
temperatures or the presence of a large excess 
of water favoured amide formation.
67Klausner has suggested that the route of 
amide formation may proceed, possibly, through 
a-nitrosation.
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r-c-nh-nh2 + hno2
(hydrazide)
0
R-^-N
nh.2
0 t,^H (+) R-ONH
JU<->
-N20
9 -R-C-NH2
(amide)
(iv) The Activated ester method: tONP)
The synthesis of peptides via the aminolysis of 
esters has long been known. The methyl and ethyl 
esters of amino acids were used in aminolysis
reactions in the earliest period of peptide 
synthesis.
68 69(Both Fischer and Curtius prepared peptides
by this approach). From the studies of Gordon,
70 71Miller, and Day ' ' it became clear that phenyl
esters aminolyse a thousand times faster than
72methyl esters. Bodanszky prepared N-protected 
amino acid p-nitrophenyl esters. (For practical 
reasons such as the ready availability of the 
phenol and good crystallisation properties of . 
its esters p-nitrophenyl esters were used) 7^'
35
For synthesis of p-nitrophenyl esters another 
coupling method has to be used (e.g. DCC method).
The preparation of such active esters is therefore 
an extra step in the synthesis of peptides. Unlike 
other coupling methods, where activated intermediates 
once formed have to be aminolysed quickly, the 
activated esters are stable and can be stored for 
longer periods. Many acylations can be performed 
with aliquots of the same material and this often 
saves time.
Activation:
(p-nitrophenyl ester)
Aminolysis of the active ester in an organic 
solvent generates p-nitrophenol and the peptide. 
The former can be removed by washing with an 
aqueous alkali.
R
Z-NH-CB-COOH + OH
(N-protected (p-nitrophenol).
amino acid). DCC Coupling
Aminolysis
Z-NH-CH-C—0¥1 ft.rn -r-n ■*no2 +
(p-nitrophenyl ester) (amino component)
Z-NH-CH-C0-NH-R2 + HO 2
(peptide) (p-ni tropheno1)
(Aminolysis is usually carried out at temperatures
Carbonyldiimidazole method: (CPI)
This method of coupling was first applied by
bonds. This is a fast coupling method.
N-P.rotected amino acids or peptides are reacted 
with CDI first in an organic solvent (e.g. 
tetrahydrofuran) to form an activated intermediate, 
an acylimidazole. At room temperature aminolysis 
is then carried out with a free amino acid salt
or an ester . The by-products are carbon dioxide 
and imidazole. The carbon dioxide escapes as gas 
and the latter can be removed by washing with an
above room temperature, 40°C).
76Anderson and Paul for the formation of peptide
41
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Activation
N:
R-C
N
J \
0-H
N
“ V
c = o
(N ,N-carbonyldiimidazole)
 R-CN = \  \0
N-C=0
h T
N 0
+ C02 + R-C-
(imidazole) (acylimidazole)
Aminolysis
0 / 
ii /R-C-N
_N
+ h2-n -r + CO,
(acylimidazole) (amino component)
/HN
=N
+ R-CO-NH-R,
(imidazole) (peptide)
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However, side reactions can occur if an excess 
of CDI is used since it reacts very readily with 
the amino component to form substituted ureas.
N
o=c
N
+ 2H_N-R' 2 1
(N,N-carbonyl- (amino component)
diimidazole).
o=cf
NH-R« / '+ 2HN
NH-R
'-N
(substituted (imidazole) 
urea)
PART II
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EXPERIMENTAL
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All melting points are uncorrected; they were recorded using a 
Gallenkamp melting point apparatus-.
t>
The infrared spectra were recorded either on a Perkin Elmer 
infrared spectrometer model 574 or a Unicam spectrometer model 
SP 200. (Nujol mulls between NaCl Plates were examined, unless 
otherwise stated).
1 13The H n.m.r. spectra and the C n.m.r. spectra were recorded
on a Bruker W90 n.m.r. spectrometer ( some ^H n.m.r. spectra were
also recorded on a Hitachi-Perkin Elmer instrument Model (R-24)) .
Elemental analyses for carbon, hydrogen, and nitrogen were - 
carried out in the Department of Chemistry, University of Surrey.
Those for chlorine were performed by:
Butterworth Laboratories Ltd.,
41, High Street,
Teddington, Middlesex, TW11 8ET
and also at,
Elemental Microanalysis Ltd.,
33, Cambridge Road.,
Kings ton-upon-Thames,
GENERAL INFORMATION ON THE CHARACTERISATION OF COMPOUNDS:
Surrey. KT2 3NQ
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77Acetylsalicylic acid: (Aspirin).
Salicylic acid (20.0g) was added to acetic anhydride (28.0ml) 
and to this mixture was also added concentrated sulphuric acid 
(2.0ml). The whole was warmed at 50 to 60° for 20 min. After 
cooling to room temperature, water (300ml) was added, and 
the product was filtered? the residue was washed with water 
several times and then dried. Acetylsalicylic acid (18.2g), had 
m.p, 126-128°C. After recrystallisation from chloroform/light petroleum 
(b.p. 40-60°C), to a constant melting -point 128-130°C, the product 
(11.Og) was obtained.
(The preparation of acetylsalicylic acid, was repeated, as above, 
to obtain a sufficient quantity for the next step).
1The H n.m.r. Spectrum, (dimethylsulphoxide):
2.5 ppm, 3H, singlet, (0CH3 )? 7.5 ppm, 4H, multiplet,
a
(aromatic protons b), ll.lppm, 1H, (broad singlet) , (C02H?
-1The infrared spectrum showed strong absorptions at 2900cm 
(broad), 1750cm-1, 1680cm-1, 1600cm"1, 1300cm-1, 1185cm-1, 
925cm-1.
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2 (i) Acetylsalicyloyl-(DL)-alanine:
Acetylsalicylic acid (18.0g.) was dissolved in dry 
tetrahydrofuran (50ml) and to it was added dry 
, triethylamine (13.8ml) and the whole was cooled to
-5°C in a Drikold-acetone bath. After stirring the mixture for 
5 min., redistilled ethyl chloroformate (9.6ml) was 
added dropwise over a period of 20 min. The mixture 
was stirred for a further 5 min. and then 
aminolysis was carried out by adding a solution of 
(DL)-alanine (8.9g) in aqueous sodium hydroxide 
(1M, 100ml) . stirring was continued at -5°C for 3hr.
Volatile material was removed at reduced pressure 30°C 
and the residual solution was acidified with dilute
hydrochloric acid, (3M), to pH 2-3, and quickly
extracted with ethyl acetate (100ml.). After having dried
the ethyl acetate extract (anhydrous sodium sulphate),
the solvent was evaporated at reduced pressure. The oily residue
was treated with light petroleum (b.p. 40-60°C) with
tooling until crystals began to form. A solid (10.Og)
m.p. of 80-90°C, was obtained and after six
recrystallisations from chloroform/light petroleum (b.p.
40-60°C), it gave acetylsalicyloyl-(DL) - alanine (1.5g) 
of m.p. 118-120°C.
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(ii)
1
The H N.M.R. spectrum, (dimethylsulphoxide):
c°-NH£CHo-C02Hf
CH.
'ococh 3a
a
1.40ppm, 3H, doublet,(J = 5.0H2), (CHrf; 2.30ppm, 3H
d
singlet, (OCOCH ); 4.40ppm, IH, multiplet (CH ) j 
a
5.70ppm, IH, (broad), (CO^ H^ ) ; 7.50ppm, 4H, multiplet-, 
(aromatic protons e); 8.5ppm, ih, doublet (J = 5.0HZ),
(NHb) .
The infrared spectrum showed strong absorptions at 
3400cm , 1750cm ^, 1715cm ^, 1640cm 1540cm ^,
1260cm 1200cm 960cm \  760cm *.
Found; C,57.33; H,5.16; N,5.35.
C12H13°5N C, 5 7.36; H,5.21, N,5.57%
The preparation of acetylsalicyloyl-(DL)-alanine was 
repeated to give acetylsalicyloyl-(DL)-alanine 
(1.8g) m.p. of 118-120°C.
Various reaction conditions were tried to improve the 
yield of the product, acetylsalicyloyl-(DL)-alanine, 
using 18.Og of the starting material, acetylsalicylic 
acid.
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1) Lower temperatures -10 to -15°C
(recrystallised from chloroform/ 1.86g 118-120°C
light petroleum (b.p. 40-60°C)) ,
2) Using excess amino acid (10.Og) 1.80g 119-122°C
(recrystallised from benzene)..
3) Using excess triethylamine
(18.8ml) (recrystallised from l.OOg 118-120°C
chloroform/light petroleum 
(b.p. 40-60°C))
4) Using less solvent (35.0ml)
(recrystallised from chloroform/ 1.50g 118-120°C
light petroleum.(b.p. 40-60°C))
5) Longer reaction time (6hr) at a 
higher temperature, (0°C),
(recrystallised from chloroform/ 5.0g 118-120°C
light petroleum.(b.p. 40-60°C))
A thin layer chromatographic system, (TLC), was developed 
in order to follow this reaction in detail.
The following solvent system proved satisfactory;
CONDITION YIELD m.p.
acetone; toluene; water; acetic acid. 
47.0ml* 50ml; 2.0ml; 1.0ml.
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Glass Plates (100 x 200mm), covered with a thin layer 
(.0.25mm) of silica gel (SG254) were employed. (SG254 
contains a fluorescent material, zinc blende).
The chromatograms were examined under ultraviolet light 
(254nm) .
TLC analysis of the product after the aminolysis step was 
carried out. The sample separated into five fractions 
a (Rf= 0.75)? b (Rf=0.53);c (Rf=0.49); d (Rf= 0.40); 
e (Rf= 0).
Fraction c_ was identified as acetylsalicylic acid and 
fraction d as acetylsalicyloyl-(DL)-alanine by use of 
markers. Fraction e was identified as (DL)-alanine by 
use of a marker and the ninhydrin test.
3 Salicyloyl-(dl)-alanine;
The acetylsalicyloyl-(DL)-alanine (0.50g), was hydrolysed 
using aqueous sodium hydroxide (lm, 25.0ml). The 
hydrolysis was carried out for 60 min. at room temperature.
After acidification at 0°C to pH 2-3 with aqueous hydrochloric 
acid (3M), the product was extracted with ethyl acetate (50ml).
The ethyl acetate extract was dried (anhydrous sodium sulphate). 
Ferric chloride (l.Og) was dissolved in aqueous methanol 
(5.0ml) and a drop of this solution was added to a small quantity 
of this extract. It gave the .characteristic violet colouration 
indicative of the unprotected salicyloyl group.
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(Acetylsalicyloyl-(DL)-alanine does not give this violet 
colouration with ferric chloride).
Tuc. analysis of the reaction mixture containing
acetylsalicyloyl-(DL)-alanine was carried out using
salicyloyl-(DL)-alanine and salicylic acid as the markers.
The fraction b (Rf= 0.53) (see p. 45 ) was now identified
as.salicyloyl-(DL)-alanine. Salicylic acid was not present 
in the reaction mixture.
4 Acetylsalicyloyl ethyl carbonate:
Acetylsalicylic acid (4.5g) was dissolved in dry tetrahydrofuran 
(12.4ml) and dry triethy1amine (3.4ml) was added. The temperature 
was brought to - 5°C in a Drikold/acetone bath. Ethyl chloroformate 
(2.4ml) was added dropwise over a period of 10 min. with stirring. 
Triethylamine hydrochloride which precipitated was filtered off.
The residual volatile material was removed at 35-40°C at reduced 
pressure. The residue was extracted with ether and the ether layer 
was concentrated at reduced pressure at 40°C. An oily 'residue was left 
which was then examined.
1The H n.m.r. spectrum of the neat oily product;
1.25ppm., 3H, triplet, (J = 5.5Hz), (CH^  ); 2.25ppm., 3H, singlet,
a
(OCOCH^); 4.30ppm., 2H, quartet, (J =5.5Hz), (CH2 ); 7.5 ppm., 
c b
4H, multiplet, (aromatic protons d).
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The C n.m.r. spectrum (deuterochloroform) showed the 
presence of four peaks at 149, 151,..* 15.8.' and 169ppm in the- 
carbonyl range. (See page 125).
9The infrared spectrum (thin film of the neat oily product
between NaCl plates) showed strong absorptions at 2900cm
1740-1820cm""1 (broad), 1604cm'"1, 1200cm"1, 1000cm"1, 910cm"1,
-1755cm
TLC analysis of the reaction mixture containing 
acetylsalicyloyl-(DL)-alanine was carried out using 
acetylsalicyloyl ethyl carbonate as the marker. The fraction 
a_ (R£= 0.75) was identified as acetylsalicyloyl ethyl carbonate 
(i.e. the "mixed anhydride" of acetylsalicylic acid).
TLC analysis showed that the formation of the mixed anhydride 
of acetylsalicylic acid a_ (Rf= 0.75) is nearly complete, leaving 
only a small quantity of the unreacted acetylsalicylic acid 
£ 0.49). Fraction £ is observed to be smaller and less
intense than fraction a.
5 (i) Acetylsalicyloyl-(dl)'-alanyl- (DL) -alanine \
Acetylsalicyloyl-(DL)-alanine (2.5g) was dissolved in 
dry tetrahydrofuran (15.0ml) and dry triethylaraine 
(1.36ml) was added. The reaction mixture was brought 
to -5°C and ethyl chloroformate (0.96ml) was added 
dropwise over a period of 10 min. (DL)-Alanine 
(0.89g) dissolved in aqueous sodium hydroxide (1M, 10.0ml) 
was added. The reaction was allowed to proceed at 0°C 
for 6 hrs., and the solvent was then removed at 30°C under
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reduced pressure. The residual solution was acidified to 
pH 2-3 using aqueous hydrochloric acid (3M). The whole 
was extracted with ethyl acetate (50.0ml), and the 
extract was dried (anhydrous sodium sulphate). The 
bulk of the ethyl acetate was removed under reduced 
pressure to leave a small volume of solution.
TLC analysis of this solution was then carried out.
The product separated into five fractions a. (Rf= 0.80), 
b (Rf= 0.53) , £ (R = 0.40) , d (Rf= 0.36) , e_ (Rf= 0.30) .
Fraction b_was identified as salicyloyl-(DL)-alanine
and fraction £ was identified acetylsalicyloyl-(DL)-alanine
by use of markers.
Fraction a was possibly a mixed anhydride of 
acetylsalicyloyl-(DL)-alanine, acetylsalicyloyl-(D,L)-alanyl 
ethyl carbonate, bearing in mind the preparation of 
acetylsalicyloyl-(DL)-alanine (see p. 47 ).
The complete removal of the solvent, ethyl acetate, left 
an oily material (1.5g)? on adding light petroleum 
(b.p. 40-60°C); a gummy material (1.15g) was recovered.
The material was not crystallisable.
(ii) The preparation of acetysalicyloyl-(DL)-alanyl-
(DL)-alanine was repeated. This time the aminolysis step 
was allowed to proceed for 8hrs., at 0°C
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until the TLC analysis showed only a little mixed 
anhydride, fraction a_ (Rf= °*8°) and, when tested 
with ninhydrin, a little (DL)-alanine. Separation of 
the reaction mixture was not attempted. (It was a 
mixture of four fractions).
6 (DL)-alanine methyl ester hydrochloride;
Into a suspension of (DL)-alanine (15.Og) in dry methanol 
(250ml) dry hydrogen chloride gas was passed for lhr, while 
the flask was kept cool in an ice/salt bath.
After refluxing for lhr., dry hydrogen chloride gas was passed
for another lhr., keeping the reaction flask cool at the same
temperature as before. The mixture was heated under reflux for
lhr. , and then all the solvent was removed at reduced pressure to obtain
the crude ester hydrochloride (15.37g) of m.p. 135-140°C. The
whole was recrystallised to a constant melting point from
methanol/diethylether to give the salt (13.55g) of m.p.
n 78149-151 C, Lit m.p. 156-158,5°C.
i H n.m.r. . spectrunt.-Cdeuterated water) »
(+)
(ND3 -CHb-C02-CH3 ) Cl" 
f n
a
1•65ppm., 3H, doublet, (J = 5.0HZ), (CH3); 4.35ppm., lH,
a
quartet, ( c y  , 3.95ppm. , 3H, singlet, (CH3 ).
c
-1The infrared spectrum showed strong absorptions at 2720cm ,
-1 -1 -1 -1 -1 -12670cm , 2600cm , 2530cm , 1750cm , 1525cm , 1255cm
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7 (i) Acetylsalicyloyl-(DL)-alanyl-(DL)-alanine methyl ester:
Acetylsalicyloyl-(DL)-alanine (5„02g) in dry acetonitrile 
(30ml) containing DCC (4.13g) was mixed with (DL)-alanine 
methyl ester hydrochloride (2.5g) in dry acetonitrile 
(60ml) containing triethylamine (2.78ml). The mixture 
was stirred at -5°C for 15 min., and then brought to room 
temperature.
TLC analysis of the reaction mixture was carried out at
regular intervals of Ihr. In each case acetylsalicyloyl-
(DL)-alanine and (DL)-alanine methyl ester were used as
markers. The reaction mixture consisted of .four fractions.
Fraction £ (Rf = 0.6 3) , fraction b (Rf = 0.57), fraction
c (R_ = 0.40) and fraction d (R_ = 0). Fraction c was — f — r —
identified as acetylsalicyloyl-(DL)-alanine by use of a 
marker.
Ninhydrin tests were performed on each chromatogram and 
fraction _d (R^  = 0) was identified as (DL)-alanine methyl 
ester which disappeared after 9hr. The reaction mixture 
was then worked up.
The by-product N‘,N-dicyclohexylurea, DCU, was filtered off 
and the residual solution was evaporated at reduced pressure 
to leave an oily residue. The residue was then extracted 
with ethyl acetate (50ml) and the solution was washed with 
dilute hydrochloric acid (0.5M, 2.x 20ml), saturated aqueous 
sodium bicarbonate solution (2 x 20ml) and finally with 
water (2 x 20ml) „ The extract was dried (anhydrous sodium 
sulphate).
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(ii)
(iii)
of two fractions a (R = 0.63), b (R = 0,57). The —  £ - - — £
ethyl acetate was evaporated at reduced pressure to give 
a residue which was a gum. On treatment with light 
petroleum (b.p. 60-80°C) and on cooling it did not 
solidify. Further purification was not attempted.
This experiment was repeated on the same scale using 
dry methylene chloride (50ml) as the solvent; it gave 
a similar result.
This preparation was repeated using the "mixed 
anhydride” method;
Acetylsalicyloyl-(DL)-alanine (5.02g) was dissolved 
in dry tetrahydrofuran (25ml). After cooling to 
-5°C, dry triethylamine (2.8ml) was added and then 
ethyl chloroformate was added dropwise (1.92ml). After having 
stirred the reaction mixture for 30 min. aminolysis 
was carried out. (DL)-alanine methyl ester hydro­
chloride (2.5g) in dry methylene chloride (10ml) 
containing dry triethylamine (2.8ml) was added to 
the reaction mixture. The reaction mixture was 
allowed to warm to room temperature and it was stirred 
for 3 days at room temperature.
TLC analysis of the extract showed it to be a mixture
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The product separated into five fractions (R^ = 0.80),
b (R = 0.63), c (R = 0.57), d (R = 0.40), e (R = 0).— r — r — r — r
Fraction d was identified as acetylsalicyloyl- (DL) -alanine, 
by use of a marker. Fraction e_ was identified as 
(DL)-alanine methyl ester using ninhydrin test. Fraction 
a_ was possibly a "mixed anhydride". Fraction Id (R^ =0.63) 
and fraction c_ (R^= 0.57) may be acetylsalicyloyl-(DL)- 
alanyl-(DL)-alanine methyl ester, a mixture of two 
diasteroisomerides.
The solvent was evaporated at reduced pressure at 40°C.
The oily residue was dissolved in chloroform (50ml). The 
chloroform solution was washed with dilute hydrochloric 
acid (0.5M, 2 x 50ml), saturated aqueous sodium 
bicarbonate solution (2 x 50ml), and finally with water 
(2 x 50ml). The extract was dried (anhydrous sodium 
sulphate). The solvent was evaporated at reduced pressure 
to leave a gummy product. It was treated with light 
petroleum (b.p. 60-80°C) with cooling. The product 
did not solidify.
TLC analysis of the product showed it to be a mixture
of two fractions b (R = 0.63), and c (R = 0.57) ■— r — t / v)
as was the case with the DCC method of coupling see 
p. 50
TLC analysis of the reaction mixture was carried out.
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The H n.m.r. spectrum (deuterochloroform) of this gum:
•CO-NHg— CH-— CONH^— CH--CO„CH
1 r L  I  CH3d.
OCOCH.
2 i c2. 2 3f
%
1. 10-1.40ppm, 6H, multiplet, (CH„ , CH~ )} 2.30ppm,
dl 2
3H, singlet, (OCOCH^ ) ; 3.50ppm., 3H, two singlets,
a
(CH-. ) ; 3.60ppm, multiplet 1H, (CH ) ; 4.50ppm, 
f C2
multiplet 1H, (CH ); 7.5ppm, 6H, multiplet, (aromatic
C1
protons e_, N H N H ^  ) .
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Alclofenac, (an anti-inflammatory drug) , was supplied by Berk 
Pharmaceuticals Ltd; Godalming, Surrey.
o
It had m.p. 90“93°C
6 o(Lit m.p. 92-93 C) .
I H n.m.r. spectrum (deuterochloroform):
3.54ppm, 2H, singlet, (CH ); 4.60ppm, 2H, multiplet, (CH );
ct 2y c5. 3ppm, 2H, multiplet, (CH2 ); 6.0ppm, IH, multiplet, (cy ;
a
6.83ppm, IH, doublet, (J = 8.3Hz), (CH^ ) ; 7.08ppm, IH, doublet, 
(J = 2.2Hz), (CHf) ; 7.13ppm, IH, double doublet, (J = 2.0Hz),
J = 8.3 Hz), (CHe) ; 11.93 ppm, IH, singlet (C02Hh) .
-1The infrared spectrum showed strong absorptions at 2900cm .
(broad), 1640 - 1720 cm d (broad), 1406 cm \  1260 cm \
-1  -1 -1 930 cm , 795 cm , 720 cm
(Note: The same TLC system used earlier in the Aspirin work,
(Section - 1), (see pp. 44,45) is used throughout in Alclofenac 
work unless otherwise stated).
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methyl ester:
Alclofenac (4.3g) was dissolved in dry tetrahydrofuran 
» (25ml) and to the mixture was added dry trie thy lami.ne
(2.8ml) and the whole was cooled to -5°C. Redistilled 
ethyl chloroformate (1.92ml) was added dropwise over 
20 min. and the reaction mixture was stirred at -5°C 
for 15 min.
TLC analysis of the reaction mixture was carried out.
The sample separated into two fractions a (Rf = 0.72) 
and b (R^  = 0.91) . Fraction a_ was identified by use of 
a marker as Alclofenac. Fraction b_ was possibly a mixed 
anhydride of Alclofenac, 4-allyloxy-3-chlorophenylacetyl 
ethyl carbonate.
Aminolysis was carried out by adding (DL) -alanine methyl 
ester hydrochloride (2.8g) in dry methylene chloride 
(10ml) containing dry trie thy lami.ne (2.8ml). The 
reaction was allowed to proceed for 3hr. at 0°C.
TLC analysis of the reaction mixture was carried out.
The sample separated into four fractions a^ (R^  = 0.72),
b (R_ = 0.91), c (R^  = 0.65) and d (R, = 0). Fraction — r — r — f
a_ was identified as Alclofenac by use of a marker. 
Fraction b_ was possibly a mixed anhydride. Fraction 
c_ was possibly the product. Fraction cl (R^  = 0) was 
identified as (DL)-alanine methyl ester using a 
ninhydrin test.
1 (i) The, attempted preparation of Alclofenac-(DL)-alanine
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The reaction mixture was allowed to warm to room temperature,
/
then stirred for a further 3hr.
TLC analysis was again carried out, it showed that fraction 
c_ was relatively smaller and less intense than fraction b.
The reaction mixture was worked up. The volatile material was 
removed by evaporation at reduced pressure and the 
residue was dissolved in chloroform (50ml). The chloroform 
solution was then washed with aqueous hydrochloric acid (0.5M) 
2 x 20ml), saturated aqueous sodium bicarbonate solution,
(2 x 20ml) and finally with water (2 x 20ml). The extract 
was dried (anhydrous sodium sulphate) and concentrated.
Light petroleum (b.p. 60-80°C) was added: a solid was 
precipitated? it (0.2g) had m.p. 59-63°C. The filtrate 
was concentrated and cooled. No more solid appeared.
The solvents were completely removed at reduced pressure to 
leave an oily residue (1.5g).
H n.m.r. spectrum of the oily residue (deuterochloroform):
1.25ppm, 3H, triplet, (J = 7.3Hz), (CH^  )? 3.51ppm, 2H,
i
singlet, (CH^  ); 4.20ppm, quartet, (J = 7.3Hz),
g ■
(CH )? 4.58ppm, 2H, multiplet, (CH ); 5.39ppm, 2H, multiplet 
h c
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(CH2 ) ; 6.14ppm, 1H> multiplet, r 6.85ppm, IH, doublet,
a
(J = 8.2Hz), (CH^ ) ; 7.06ppm, IH, double doublet, (J = 2.1 Hz
J = 8.2 Hz) (CH2 ) ; 7.28 ppm, IH, doublet, (J=2.1 Hz) , (CHf)
e
13The C n.m.r. spectrum (deuteroch loro form) showed the 
presence of two signals at 153 and 171ppm, 
in the carbonyl group range.
The infrared spectrum showed strong absorptions at 
1820cm 1735cm \ 1600cm 1, 1500cm 1, 1280cm 1, 1255cm 1,
1240cm"1' 1100cm"1, 1060cm"1, 1030cm"1, 995cm"1' 930cm"1,
-1 -1 870cm , 800cm
1H n.m.r. spectrum (deuterochloroform) of the solid:
1.36ppm, 3H, doublet, (J = 7.0Hz), (CH ); 3.49ppm, 2H,
Jh
singlet, (CH ); 3.73ppm, 3H, singlet (CH ); 4.7ppm, 
e 8i
3^ multiplet, (CH , CH2 ); 5.4ppm, 2H, multiplet,
q c
(CH2 ); 6.1ppm, 2H, multiplet, (NHf, c y  } 7.13ppm,
a
3H, multiplet, (aromatic protons d) .
The infrared spectrum showed strong absorptions at 
3260cm"1, 1755cm"1, 1730cm"1, 1610cm"1, 1540cm"1, 1495cm"1, 
1250cm 1, and 1050cm 1.
- 58 -
allowed to proceed for 3 days at room temperature. After 
working up the reaction mixture no improvement in the 
product yield was obtainedo The solid (200mg) had m.p.
58-63°C.
(iii) This experiment was again repeated, aminolysis being
allowed to proceed at 40°C for 3hr. TLC analysis of the 
reaction mixture showed the presence of unreacted mixed 
anhydride and unreacted (DL)-alanine methyl ester. The 
whole was heated under gentle reflux for 2hr. After 
working up the reaction mixture the yield was no better 
than that obtained previously (200mg).
(iv) To Alclofenac (4.3g) in dry methylene chloride (30ml)
was added (DL)-alanine methyl ester hydrochloride (2.8g) 
suspended in dry methylene chloride (10ml) containing 
dry triethy1amine (2.8ml). DCC, (4.1g) was added and 
the reaction mixture was stirred at room temperature.
After overnight stirring the reaction mixture was cooled 
0°C and the by-product N^N-dicyclohexylurea, DCU was 
filtered off. The volatile material was removed by 
evaporation under reduced pressure. The semi-solid 
residue was dissolved in chloroform (50ml). The 
chloroform solution was washed with aqueous hydrochloric 
acid (0.5M, 2 x 20ml), saturated aqueous sodium bicarbonate 
solution (2 x 20ml) and finally with water (2 x 20ml).
(ii) The experiment was repeated; this time aminolysis was
The extract was dried (anhydrous sodium sulphate) and then
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evaporated to a small yolume under reduced pressure.
Light petroleum (50ml, b.p. 60-80°C) was added to 
obtain a solid product (2.0g) m.p. 58-63°C. After 
recrystallisation from chloroform/light petroleum
t
(b.p.'. 60-80°C) the product,
Alclofenac-(DL)-alanine methyl ester (1.4g) of m.p.
60-63°C was obtained.
Found: C,57.54; H,5.80*f N,4.41j Cl,11.40.
C,cH,oN0.Cl requires C,57.79; H,5.82; N,4.49; Cl,11.37% 
lb  l o  4
1The H n.m.r. spectrum and the infrared spectrum were 
both identical to those obtained previously (see p. 57).
2 Alclofenac-(DL)-alanine:
Alclofenac-(DL)-alanine methyl ester (2.0g) was suspended in 
■ acetone (20ml). Aqueous sodium-hydroxide (IM, 8.0ml) was added 
and the mixture was gently warmed to effect solution, and then 
heated at 40°C for 20 min.After the solution had been cooled the pH was 
adjusted to 2-3 using dilute hydrochloric acid (3M) and the 
product was extracted with ethyl acetate (40ml). The extract 
was dried (anhydrous sodium sulphate). The solvent was 
evaporated at reduced pressure to leave a solid residue (1.8g)j 
it had m.p. 120-124°C. After recrystallisation from ethyl- 
acetate/light petroleum (b.p. 60-80°C) the product, Alclofenac- 
(DL)-alanine (1.6g) of m.p. 123-124°C was obtained.
TLC analysis of the product showed it to be a single substance 
(Rf = 0.36).
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1,H n.m.r. spectrum ' (dimethylsulphoxide);
CH-C0-NH-CH-C0_H.. 2 f | g 2 i
r r  C1
c a
1.27ppm, 3H, doublet, (J = 7.5Hz), (CH^  ); 3.40ppm, 2H, singlet,
multiplet, (CH2 ); 5.30ppm, 2H, multiplet, (CH2 ); 6.0ppm, IH, 
c a
multiplet, (CH^); 7.1ppm, 3H, multiplet, (aromatic protons d) ;
8.38ppm, 2H, doublet, (J = 7.5Hz), (NHf) ; 12.5ppm, IH, (broad
singlet) , (C02H_J .
3 Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester:
Alclofenac-(DL)-alanine (0.622g) was dissolved in dry tetrahydrofuran 
(10ml). To the solution was added (DL)-alanine methyl ester 
hydrochloride (0.3g) in dry methylene chloride (3.0ml) containing 
dry trie thy1amine (0.3ml).
e
The infrared spectrum showed strong absorptions at 3290cm 
1675cm-1, 1660cm-1, 1500cm-1, 1255cm"1.
Found; C,56.54; H,5.46; N,4.74; Cl,11.74.
C H NO Cl requires C,56.47; H,5.42; N,4.71; Cl,11.90%14 16 4
DCC (0.413g) was added and the reaction mixture was stirred at 
room temperature.
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TLC analysis of the reaction mixture was carried out after 4hr.
(Rf = 0.36) , and £ (R^  = 0) . Fraction Id was identified as 
Alclofenac-(DL)-alanine using a marker. Fraction £ was identified
was possibly the product.
After being stirred overnight, the reaction mixture was worked up. DCU 
was filtered off. The volatile material was evaporated at reduced 
pressure. The.semi-solid residue was dissolved in chloroform (20ml). 
The chloroform solution was washed with aqueous hydrochloric acid 
(0.5M, 2 x 20ml), saturated aqueous sodium bicarbonate solution 
(2 x 20ml) and finally with water (2 x 20ml) . The extract was 
dried (anhydrous sodium sulphate). The solvent was evaporated at 
reduced pressure to leave a small volume of material. Light 
petroleum (b.p. 60-80°C) was added to obtain a solid product 
(400mg) of m.p. 100-105°C. After recrystallisation from chloroform/ 
light petroleum (b.p. 60-80°C) a solid product,
Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester (200mg) of 
m.p. 105-107°C was obtained.
H n.m.r. spectrum (deuterochloroform). :
The sample separated into.three fractions a (R_ = 0.45), b— f —
as (DL)-alanine methyl ester using a ninhydrin test. Fraction a
h
0CH~CH=CH2 b 2a
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1.34ppm,- 6H, two multiplets, (CH- , CH )? 3.46ppm, 2H, singlet,
' 3h \
(CH2 )? 3.72ppm, 3H, twp singlets, (CH^  )? 4.5ppm, -4H, multiplet,
e • I .(CH , CH., CH )? 5. 5ppm, 2H, multiplet, (CH )? 6.0ppm, 1H,y j  ^ a,c a
multiplet, (CH.)? 6.54ppm, 1H, (broad), (NH,)? 7.00ppm, 4H,
« -1-
multiplet, (aromatic protons d, NHf).
The infrared spectrum showed strong absorptions at 3270cm ,
1745cm”1, 1640cm-1, 1540cm-1, 1500cm-1, 1215cm-1, 1160cm"1, 
1055cm-1.
Found? C,56.44? H,5.99? N,7.22? Cl,8.99.
C18H23N2°5 Cl requires C,56.46; H,6.05? N,7.32? Cl,9.26%
4 Alclofenac-glycine ethyl ester:
Alclofenac (4.3g) was dissolved in dry tetrahydrofuran (20ml).
To the solution was added glycine ethyl ester hydrochloride 
(2.85g) in dry chloroform (30ml) containing dry triethylamine 
(2.8ml).
DCC (4.1g) was added and the reaction mixture was stirred 
overnight at room temperature.
TLC analysis was then carried out. The sample separated into 
three fractions a (R_ = 0.80 ) , b (R = 0.72) , c (Rj. = 0) .— f — f — X
Fraction b^ was identified as Alclofenac by use of a marker.
Fraction c_ was identified as glycine ethyl ester using a
ninhydrin test. Fraction a was possibly the product.
DCU was filtered off and the volatile material was evaporated at
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reduced pressure. The semi-solid.residue was dissolved in 
chloroform (,100ml) . The chloroform solution was washed with, 
dilute hydrochloric acid (0.5M, 2 x 50ml), saturated aqueous- 
sodium bicarbonate (2 x 50ml) and finally with water (2 x 50ml) .
The extract was dried (anhydrous sodium sulphate).
The solvent was evaporated at reduced pressure to leave a small 
volume of material. Light petroleum (b.p. 60-80°C) was added 
to obtain a solid (2.0g) of m.p. 70-73°C. After re crystallisation 
from chloroform/light petroleum (b.p. 60-80°C), the product, 
Alclofenac-glycine ethyl ester (1.4g) of m.p. 73-76°C was obtained.
1H n.m.r. spectrum (deuterochloroform):
CH-C0-NH-CH — CO -CH— CH z I Z A z, J.e g h r
Cl
0CH-CHgCH2 
c a
1.16ppm, 3H, triplet, (J = 7.0Hz), (CH^  ); 3.40ppm, 2H, singlet,
i
(CH2 ); 3.81ppm, 2H, doublet, (J = 5.9Hz), (CH2 ); 4.09ppm, 2H, 
e g
quartet, (J = 7.0Hz), (CH )f 4.6ppm, 2H, multiplet, (CH2 );
h c
5.40ppm, 2H, multiplet, (CH2 ) , 6.05ppm, IH, multiplet, (CH^ ) ,
a
7.15ppm, 3H, multiplet, (aromatic protons d) ; 8.40ppm, IH, 
triplet, (J = 5.9Hz), (NHf) .
The infrared spectr\jm showed strong absorptions at 3290cm 1,
-1 -1 -1 -1 -1 -11750cm , 1650cm , 1540cm , 1500cm , 1250cm , 1190cm
1055 cm”-1, 1015 cm”1.
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Found; C,57.94; H,5.77; N,4.78; Cl,.11.17.
C15H18N04C1 rec5udres C,57. 79; H,5_.82; N,4.49; Cl,11.37%
5 Alclofenac-glycine methyl ester:
Alclofenac (4.3g) was dissolved in dry tetrahydrofuran (20ml).
To the solution was added glycine methyl ester hydrochloride 
(2.3g) in dry chloroform (20ml) containing dry triethyl amine 
(2.8ml).
DCC (4.1g) was added and the reaction mixture was stirred 
overnight at room temperature.
TLC analysis was then carried out. The sample separated into
three fractions a (R = 0.85), b (R~ = 0.72), c (R_ = 0) .— f — x — x
Fraction Id was identified as Alclofenac by use of a marker. 
Fraction _c was identified as glycine methyl ester using a 
ninhydrin test. Fraction .a was possibly the product.
DCU was filtered off and the volatile material was evaporated at 
reduced pressure. The semi-solid residue was dissolved in 
chloroform (100ml). The chloroform solution was washed with 
aqueous hydrochloric acid (0.5M, 2 x 50ml), saturated aqueous 
sodium bicarbonate solution (2 x 50ml) and finally with water 
(2 x 50ml). • The extract was dried (anhydrous sodium sulphate).
The solvent was evaporated at reduced pressure to leave a 
small volume of material. Light petroleum (b.p. 60-80°C) was
added to obtain a solid (2.0g) of m.p. 68-73°C. After
recrystallisation from chloroform/light petroleum (b.p. 60-80°C)
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the product, Alclofenac-glycine methyl ester.(1.5g) of m.p.
70-73°C was obtained.
*H n.m.r. spectrum (deuterochloroform):
.CH—CO -NH-CH —  CO -CH 3 
^ e 9 h
d 0CH-CH=CH2 
c a
3.53ppm, 2H, singlet, (CH2 ) ? 3.70ppm, 3H, singlet, (CH3 )?
e h
4.01ppm, 2H, doublet, (J = 5.3Hz), 4.6ppm, 2H, multiplet,
g
(CH2 )? 5.3ppm, 2H, multiplet, (CH2 )? 6.0ppm, 2H, multiplet,
c a
(CH^ , NH^)? 7.0ppm, 3H, multiplet, (aromatic protons d).
-1The infrared spectrum showed strong absorptions at 3240cm ,
1745cm-1, 1645cm"1, 1555cm"1, 1500cm-1, 1250cm"1, 1215cm-1, 
1055cm ?
Found? C,56.44; H,5.73; N,4.93? Cl,11.74?
C14H16N°4C1 C,56.47? H,5.42? N,4.71? Cl, 11.90%
6 Alclofenac-glycine:
Alclofenac glycine methyl ester (0.594g) was suspended in acetone 
(8.0ml) to which was added aqueous sodium hydroxide solution 
(IM, 4.0ml) and the whole was warmed to 40°C for 30 min.
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After the solution had been cooled to 0°c the pH was adjusted to 2-3 using 
dilute hydrochloric acid (-3M) and quickly extracted with ethyl acetate
(20ml). The extract was dried (anhydrous sodium sulphate).
The solvent was evaporated at reduced pressure to leave a solid 
residue (450mg) of m.p. 115-119°C. After recrystallisation from 
ethyl acetate/light petroleum (b.p. 60-80°C) the product, 
Alclofenac-glycine, (350mg) of m.p. 117-119°C was obtained.
TLC analysis of the product showed it to be a single substance 
(Rf = 0.50).
1H n.m.r. spectrum (dimethylsulphoxide):
CH— CO-NH-CHr-CO_H Z r  Z z he g
0CH-CHgCH2 
c a
3.50ppm, 2H, singlet, (CH2 ); 3.70ppm, 2H, doublet, (J = 5.7Hz),
e
(CH2 ); 4.6ppm, 2H, multiplet, (CH2 ); 5.4ppm, 2H, multiplet,
g c
(CH2 ); 6.0ppm, IH, multiplet, (CH^ ) ; 7.2ppm, 3H, multiplet, 
a
(aromatic protons d) ; 8.30ppm, IH, triplet, (NH ); 12.5ppm,
f
(broad singlet) , (CO^ H^ ) .
The infrared spectrum showed strong absorptions at 3280cm ,
1720cm*"1, 1645cm-1, 1545cm"1, 1500cm"1, 1250cm"1, 1055cm-1,
-1920cm
Found; C,54.86; H,4.70; N,4.94; Cl,12.72.
C 13H 14N(?4C1 rec5uires C,55.03; H,4.97; N,4.94; Cl, 12.50%
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7 Alclofenac-(L)-histidine methyl ester:
Alclofenac (4#3g) was dissolved in dry tetrahydrofuran (40ml) .
To the solution was added (L)-histidine methyl-ester 
dihydrochloride (4.8g) in dry chloroform (20ml) containing dry 
triethylamine (5.6ml).
DCC (4.1g) was added and the reaction mixture was stirred 
overnight at room temperature.
TLC analysis was then carried out using a different solvent 
* system;
1-butylamine; acetone 
10ml ; 90ml
The sample separated into three fractions a_ (R = 0.73), b 
(R^  = 0.60) , and c_ (R^  = 0) . Fraction ]b  was identified as 
Alclofenac by use of a marker. Fraction c_ was identified 
as (L)-histidine methyl ester using a ninhydrin test. Fraction 
£ was possibly the product.
DCU was filtered off and the volatile material was evaporated at 
reduced pressure. The semi-solid residue was dissolved in 
ethyl acetate (50ml). The ethyl acetate solution was washed with 
dilute hydrochloric acid (pH 4.6, 2 x 100ml), saturated aqueous 
sodium bicarbonate solution (2 x 100ml), and finally with water 
(2 x 100ml). The extract was dried (anhydrous sodium sulphate). 
The solvent was evaporated at reduced pressure to leave a solid 
residue (3.0g) of m.p. 89-93 C. After recrystallisation from 
ethyl acetate/light petroleum (b.p. 60-80°C) the product,
Alclofenac- (L) -histidine methyl esterr (2.2g) of m.p. 90-93^0 was 
obtained.
n.m.r. spectrum (dimethylsulphoxide):
c a
3.05ppm, 2H, doublet, (J = 5.3Hz), (CH )? 3.48ppm, 2H, singlet,
h
(CH2 ) j 3.64ppm, 3H, singlet (CH^  )? 4.7ppm, 3H, multiplet,
e j
(CH , CH2 )? 5.4ppm, 2H, multiplet, (CH2 )? 6.0ppm, 1H, multiplet, 
c a
(CH^ ) ; 7.1ppm, 6H, complex of signals, (3 aromatic protons d,
CH , CH , NH )? 9.4ppm, lH, (broad) (NH ).
1 2 3
The infrared spectrum showed strong absorptions at 3180cm ,
1740cm"1, 1650cm"1, 1580cm"1, 1500cm-1, T290cm-1, 1260cm"1,
1255cm"1, 1240cm"1, 1150cm"1, 1090cm"1, 1060cm"1, 1000cm"1,
-1 -1 -1790cm , 720cra , 620cm
Found: C,57.57; H,5.59? N,10.88? Cl,9.05.
C18H20N3°4C1 re<Iuires C,57.22? H,5.34? N,11.12? Cl,9. 38%
20°
[a3D = -11.58°
8 (i) The attempted preparation of Alclofenac-glycyl-(L)- 
histidine methyl ester:
Alclofenac-glycine (4.3g) was dissolved in dry tetrahydrofuran
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(40ml). To the solution was added (L)-histidine methyl 
ester dihydrochloride (4.84g) in dry chloroform (,20ml) 
containing dry triethylamine (5.60ml) .
DCC (4.1g) was added and the reaction was stirred
overnight at room temperature:
TLC analysis was then carried out (using the solvent
system as on p. 67). The sample separated into four
fractions a (Rf = 0.70), b (Rf = 0.56), c_ (Rf = 0.50),
d (Rj. = 0) . Fraction c was identified as Alclofenac-
—  r —
glycine by use of a marker. Fraction d. was identified 
as (L)-histidine methyl ester using a ninhydrin test.
Either fraction a. or fraction b_ could be the product.
DCU was filtered off and the volatile material was evaporated 
at reduced pressure. The semi-solid residue was dissolved 
in ethyl acetate (100ml). The ethyl acetate solution was 
washed with aqueous hydrochloric acid (pH 4.6, 2 x 100ml), 
saturated aqueous sodium bicarbonate solution (2 x 100ml), 
and finally with water. The extract was dried (anhydrous 
sodium sulphate). The solvent was evaporated at reduced 
pressure to leave a solid residue (l.lg) of m.p. 145-149°C.
The solid product was treated with hot chloroform (30ml) 
and the insoluble material was filtered off. Light 
petroleum (b.p. 40-60°C) was added (50ml) and a solid 
(0.7g) of m.p. 147-150°C was obtained.
n.m.r. spectrum (deuterochloroform)
(I) N-(Alclofenac-glycyl)-dicyclohexylurea
(II) 0-(Alclofenac-glycyl)-dicyclohexylurea
1.50-2.OOppm, 22H, (two broad signals), (cyclohexyl
protons h); 3.50ppm, 2H, singlet, (CH2 ); 4.03ppm, 2H,
e
doublet, (J = 5.0Hz), (CH2 ); 4.54ppm, 2H, multiplet,
g
(CH2 ); 5.4ppm, 2H, multiplet, (CH^  )f 5.9ppm, IH, 
c a
multiplet, (CH^ ) ; 6.7ppm, (broad triplet) , (NHf) ;
7-3ppm/ 4H, multiplet, (aromatic protons d, N£+)•
The infrared spectrum showed strong absorptions at 
3300cm 1 (broad)f 1715cm 1, 1665cm 1, 1640cm 1,
1555cm 1, 1530cm 1, 1500cm 1, 1270cm 1, 1230cm 1,
-1 -1 -1 1160cm , 1060cm , 740cm
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C n.m.r. spectrum (deuterochloroform) :
Part Formula I Part Formula II
171.4ppm 168.2ppm 
J/ I
CO-NH 
153.4ppm
CH-C 0 -NH - CH r CO“N z z |
152.^ lppm 0CHrCa^Cvt
171.4ppm
168.2ppm
4> Y  —  N 153.4ppm
CH-CO-NH-CH-CO-.O— C.Y ■2 2 ,
HN 
I
Cl
_ och-ch=ch 152.4ppm 2 x2
Found? C,63.4 7? H. 7* 26 ? N,8.61 ? Cl, 7.02.
C26H36N3°4C1 quires C,63.72 ; h ,7.41? N,8.58? Cl,7.23%.
(ii) This experiment was repeated using (2.83g) of Alclofenac-
lglycine and the H n.m.r. spectrum of the product was 
identical to that obtained previously in (i) (see p.7 0 ).
(iii) Five small scale preparations were carried out using 
(2.83g')of Alclofenac-glycine in each case. The crude 
products, solids,were bulked and washed with chloroform 
a few times. The chloroform insoluble fraction (600mg) 
of m.p. 151-155°C was recrystallised from acetone/light 
petroleum (b.p. 60-80°C) to give the product, 
Alclofenac-qlycyl-(L)-histidine methyl ester (520mg)
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of m.p. 153-155 C.
H n.m.r. spectrum ' (dlmethylsulphoxide) :
CH-CO-NH-CH— CO-NH^CHrCO-CH3f 2
N
A ,
CH,
^ H _
m
OCH-CHgCHz
1 Hk 3 2
2.89ppm, 2H, doublet, (J = 6.7Hz), (CH2 ); 3.43ppm, 2H,
g
singlet, (CH2 ); 3.58ppm, 3H, singlet, (CH3 ); 3.71ppm, 
e m
2H, doublet, (J = 5.85Hz), (CH ); 4.5ppm, 3H, multiplet,
1
(CH2 , CH±); 5.3ppm, 2H, multiplet, (CH2 )? 6.0ppm, IH, 
c a
multiplet, (CH^); 7.3ppm, 5H, multiplet, (aromatic
protons d, CH , CH ); 8.4ppm, 2H, multiplet, (NH ,
k l  2
N jy .
(NH ) was not observed in the range 0-13ppm).
3
The infrared spectrum showed strong absorptions at 
3290cm"1, 3190cm"1, 1735cm"1, 1660cm"1, 1640cm"1, 
1560cm”1, 1260cm"1, 1220cm"1.
Found? C,55.21; H,5.36? N,12.61; Cl,8.18.
C20H23N4°5C1 C,55.23; H,5.33; N,12.89; Cl,8. 15%
9 Alclofenac-(L)-histidyl hydrazide:
Alclofenac-(L)-histidine methyl ester (300mg) was dissolved in
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absolute ethanol (10ml). To it was added hydrazine hydrate (62%, 3.0ml) 
The mixture w.a,s left standing oyernight at room temperature. The 
solid product was filtered off and then washed with dry ether and then 
dried. The product, Alclofenac-(L)-histidyl hydrazide, had m.p. of 
203-206°C.
1The H n.m.r. spectrum of this compound was unobtainable because 
the compound was found to be insoluble in the common n.m.r. 
solvents. It was found to be soluble in deuterated trifluoroacetic 
acid, however, the TLC investigation (using the solvent system 
as on p. 67) showed evidence of decomposition in this medium.
The sample separated into two fractions a (R^  = 0.67) , b (R^  0.33) .
No attempt was made to identify these fractions.
-1 -1The infrared spectrum showedstrong absorptions at 3260cm , 3160cm ,
(broad), 1650cm 1 (broad), 1570cm 1, 1500cm 1, 1270cm 1, 1250cm 1
1090cm 1 , 1010cm 1, 900cm 1, 950cm 870cm 1, 800cra 1, 680cm 1,
-1620cm
The compound could not be recrystallised as it was found to be 
insoluble in common organic solvents;
chloroform, carbon tetrachloride, methanol, ethanol, dimethylformamide, 
acetone, tetrahydrofuran, cyclohexane, nitrobenzene, benzene, dioxan, 
dime thy lsulphoxide, diethyl ether. it was also found to be insoluble 
in water.
The mass spectrum showed the molecular ion at / 377.
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C . _H N 0 Cl requires C,54.04; H,5.34; N,18.54? Cl,9. 38%
1 /  Z U D D
10 (i) Alclofenac-(L)-histidyl-glycine ethyl ester;
Alclofenac-(L)-histidine hydrazide (1.5lg) in dilute 
hydrochloric acid (1M, 12ml) was suspended in ethyl acetate - 
(16ml) and the whole was cooled in an ice bath. A cold 
solution of sodium nitrite (280mg) in distilled water 
(2ml) was added. After 2 min, cold potassium carbonate 
(50% w/v, 2.4ml) was added and the mixture was placed 
in a separating funnel. The aqueous solution was 
separated from the organic phase. The former was 
extracted with ethyl acetate (2ml) and the combined 
organic extracts were dried (anhydrous sodium sulphate).
To a suspension of glycine ethyl ester hydrochloride 
(0.558g) in dry ether (16ml) at 0°C was added aqueous 
potassium carbonate (50% w/v, 6.0ml). The mixture was 
placed in a separating funnel and the organic layer 
separated and then dried (anhydrous sodium sulphate).
The two dried extracts were mixed and left to stand 
at 0°C for 24hr. The crude solid product, which formed, 
was filtered off, washed with a little ethyl acetate and 
dried. The product (500mg) had an m.p. of 160-170°C.
(ii) Three preparations on this scale were carried out and the 
products were bulked. After recrystallisation from 
acetone/light petroleum (b.p. 60-80°C) the product,
Found; C,53.97; H,5.43; N,18.42; Cl,9.60.
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Alclofenac-(L)-histidy1-glycine ethyl ester 
(750mg) of jm.p. 165-167°C was obtained.
1H n.m.r. spectrum (dimethylsulphoxide):
CH2-O0-NH—  9Hrc0-NHr CHr C0r CH2
2  g  C H  nN ) 1 3h
,  1  1
d 0CH^-CH=CH2 k3
a
1.15ppm, 3H, triplet, (J = 7.0Hz), (CH ); 2.9ppm, 2H,
h
doublet, (J = 5.3Hz), (CH ); 3.30ppm, 2H, singlet,
1
(CH^  ) 3.80ppm, 2H, doublet, (J = 6.1Hz), (CH2 ); 4.08ppm, 
“e g
2H, quartet, (J = 7.0Hz), (CH2 ); 4.5ppm, IH, multiplet,
n
(CH.); 4.6ppm, 2H, multiplet, (CH2 ); 5.35ppm, 2H,
1 c
multiplet, (CH2 ); 6.0ppm, IH, multiplet, (CH^ )} 7.1ppm, 
a
5H, multiplet, (aromatic protons d, CH CH ), 8.25ppm,
* r  2
IH, doublet, (J = 8.35Hz), (NH^ ) ; 8.40ppm, IH, triplet,
(J “ 6.1 5 Hz) , (NH ); 11.70ppm, IH, (broad) , (NH ) .k k3
The infrared spectrum showed strong absorptions at 
3290cm 1, 1750cm ri 1650cm 1 (broad), 1520cm 1 (broad),
1500cm , 1280cm” , 1250cm” , 1220cm" , 1060cm" , 1020cm"
-1 -1 -1 990cm , 820cm , 620cm
Found; C,56.14; H,5.35; N,12.16; Cl,7.98.
C21H25N405C1 rec*uires C,56.18; H,5.61; N,12.48; Cl,7.90%
- 76 -
Alclofenac ■ (2,3g) was- dissolved in dry tetrahydrofuran (10ml).
To the solution was added dry triethylamine Cl.4ml) and the 
whole was cooled to -5°C. Redistilled ethyl chloroformate 
(0.92ml) was added dropwise during lOmin. The whole was then 
stirred for a further lOmin.
TLC analysis was then carried out. The sample separated into
two fractions, a (R_ = 0.91) and b (R_ = 0.72). Fraction b— r — f —
was identified as Alclofenac by use of a marker. Fraction a_ 
was possibly a mixed anhydride of Alclofenac i.e., 
4-allyloxy-3-chlorophenyl acetyl ethyl carbonate. Aqueous ammonia
(d 0.880, 2ml) was added. The mixture was allowed to warm to room 
temperature and stirred for lhr.
TLC analysis was again carried out. The sample separated into
three factions a (R_ = 0.91), b (R^  = 0.72) and c (R, = 0.46).— f — r — f
Fraction b_ was identified as Alclofenac by use of a marker. 
Fraction £ was possibly the mixed anhydride of Alclofenac and 
Fraction £ was possibly the product.
The volatile material was evaporated at reduced pressure. The 
semi-solid residue was dissolved in ethyl acetate (50ml). The 
ethyl acetate solution was washed with dilute hydrochloric 
acid (IM, 2 x 50ml), saturated aqueous sodium bicarbonate 
solution (2 x 50ml) and finally with water (2 x 50ml). The 
extract was dried (anhydrous sodium sulphate) and concentrated 
to half its original volume. Light petroleum (b.p. 40-60°C) 
was added to precipitate the solid (210mg) of m.p. 109-111°C.
1 Alclofenac amide;
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After recrystallisation from ethyl acetate/light petroleum 
(b.p. 40—60°C) the product, Alclofenac amide (140mg) of 
m.p. 110-112°C was obtained.
H n.m.r. (dimethylsulphoxide)
CHCO-NH 
2e f
I X
Cl
OCH— CH=CH_2 b 2 a c
3.30ppm, 2H, singlet, (CH2 ); 4.63ppm, 2H, multiplet, (CH2 )?
e c
5.3ppm, 2H, multiplet, (CH2 ); 6.0ppm, IH, multiplet, (CH^ ) ?
a
7.1ppm, 5H, multiplet, (aromatic protons d, NH ).
-1The infrared spectrum showed strong absorptions at 3360cm
-1 -1 -1 -1(broad), 3180cm (broad), 1640cm , 1500cm , 1270cm ,
1250cm"1, 1060cm"1, 795cm"1.
Found: C,58*28? H,5.20; N,6„14; Cl,15.50
C11H12N02C1 C,58054; H,5.36; N,6.21; Cl,15.71%
12 (i) Alclofenac-(DL)-alanine amide:
Alclofenac—(DL)—alanine (2.975g) was dissolved in dry 
tetrahydrofuran (10ml). To the solution was added dry 
triethylamine (1.4ml) and the whole was cooled to -5°C0 
Redistilled ethyl chloroformate (0.92ml) was added drop- 
wise during 10 min. The whole was then stirred for a 
further 10 min.
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TLC analysis was carried out. The sample separated into 
two fractions a_ (R^  = 0.82) and fraction b (Rf = 0.36).
Fraction b was identified as Alclofenac-(DL)-alanine using 
a marker. Fraction a. was possibly the mixed anhydride of 
Alclofenac-(DL)-alanine, i.e., 4-allyloxy-3-chlorophenylacetyl- 
(DL)-alanyl ethyl carbonate. Aqueous ammonia (d 0.880, 2.0ml)
was added and the mixture was allowed to warm to room
temperature and stirred for lhr. TLC analysis was again 
carried out. The sample separated into three fractions p 
(R^  = 0.82) , b_ (R^  = 0.36) and c_ (R^  = 0.38) . Fraction b_ 
was identified as Alclofenac-(DL)-alanine using a marker. 
Fraction _c was possibly the product and fraction a_ was 
possibly the mixed anhydride of Alclofenac-(DL)-alanine.
The volatile material was evaporated at reduced pressure.
The semi-solid residue was dissolved in ethyl acetate 
(100ml). The ethyl acetate solution was washed with 
dilute hydrochloric acid (IM, 2 x 100ml), saturated aqueous 
sodium bicarbonate (2 x 100ml) and finally water (2 x 100ml). 
The extract was dried (anhydrous sodium sulphate) and
concentrated to a small volume. Light petroleum (b.p. 40-60°C)
was added to precipitate the solid (350mg) of m.p. 153-158°C.
13 (ii) The experiment was repeated to obtain more product (350mg) 
of m.p. 155-158°C. The products of the two experiments 
were bulked. After recrystallisation from ethyl acetate/light 
petroleum (b.p. 40-60°C) the solid product, Alclofenac-(DL)- 
alanyl-amide (650mg) of m.p. 155-158°C was obtained.
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1
: H n.m.r. spectrum . (dimbthylsulphoxide)
1.15ppm? 3H, doublet, (J = 6.9Hz) , (CH„ )? 3.40ppm, 2H,
h
singlet, (CH ); 4.19ppm, IH, quintet, (CH )? 4.62ppm, 
e ^
2H, multiplet, (CH2 )? 5.35ppm, 2H, multiplet, (CH2 )?
c a
6olppm, IH, multiplet, (CH^ ) ? 7.15ppm, 5Hf multiplet,
(3 aromatic protons d, NH )? 8.lOppm, IH, doublet,
k
(J = 7 „ 6Hz) , (NHf) .
The infrared spectrum showed strong absorptions at 
3370cm"1, 3280cm"1, 3180cm"1, 1675cm"1, 1625cm"1,
1535cm"1, 1500cm"1, 1250cm"1, 1055cm"1.
Found: C,56.76? H,5.99? N,9,v35? Cl,11.64.
C14H17N203C1 requires C,56.66? H,5.77? N,9.44?
Cl,11.95%.
4 The attempted preparation of Alclofenac-glycy1-glycine methyl ester
Alclofenac-glycine (2.83g) was dissolved in dry tetrahydrofuran 
(20ml) and to it was added glycine methyl ester hydrochloride 
(1.27g) in dry chloroform (30ml) containing dry trie thy1amine (1.4ml).
DCC (2„06g) was added and the reaction mixture was stirred overnight at 
room temperature.
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TLC analysis was then carried out. The sample separated into 
three fractions a. (Rf = Q.55) , h (,Rf = Q.5Q) and £ (Rf 0) .
Fraction b was identified as Alclofenac glycine, by use of a 
marker. Fraction £ was identified as- glycine methyl ester using 
the ninhydrin test. Fraction £ was possibly the product.
DCU was filtered off. The volatile material was evaporated at 
reduced pressure and the semi-solid residue was dissolved in 
chloroform. The chloroform solution was washed with dilute 
hydrochloric acid (pH 2-3, 2 x 50ml), saturated aqueous sodium 
bicarbonate solution (2 x 50ml) and finally with water (2 x 50ml) .
The extract was dried (anhydrous sodium sulphate) . The solvent 
was evaporated to obtain a crude solid product (800mg) of m.p.
144-150°C.
1The H n.m.r. spectrum (deuterochloroform) and the infrared spectrum 
were similar to those obtained for the side product (which could be either 
N-(Alclofenac-glycyl)-dicyclohexylurea or 0-(Alclofenac-glycyl)- 
dicyclohexylurea) obtained earlier (see p. 70).
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Alclofenac-glycine methyl ester (2.0g) was dissolved in absolute 
ethanol (16ml) 0 To the solution was added hydrazine hydrate (62%, 
202ml) and the mixture was left to stand at room temperature 
overnighto
The product formed was gelatinous. It was filtered off as a white 
gel, then washed with dry ether„ When dried it set into a grey 
heterogenous solid (l08g) of m.p. 101-112°C. Purification was not 
attempted.
-1The infrared spectrum showed strong absorptions at 3320cm ,
1645cm"1, 1615cm"1, 1570cm"1, 1500cm"1, 1260cm"1, 1240cm"1,
1055cm"1.
16 Alclofenac-glycyl-glycine:
Alclofenac-glycine (2„83g) was dissolved in dry tetrahydrofuran
I(10ml) 0 To it was added N,N-darbonyldiimidazole, CDI, (L62g) 
and the reaction mixture was stirred for 30 min. until effervescence 
ceased^ Glycine (0.75g) in aqueous sodium hydroxide (Im , 10o0ml) 
was then added and the reaction mixture was stirred at room 
temperature for lhr.
\
TLC analysis was then carried out. The sample separated into three 
fractions. £ (R^  = 0.50), b (R^  = 0.30), £ (R^  = 0)„ Fraction a 
was identified as Alclofenac-glycine by use of a marker. Fraction 
£ was identified as glycine using a ninhydrin test. Fraction b 
was possibly the product.
15 The attempted preparation of Alclofenac-glycine hydrazide:
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The reaction mixture was then poured into dilute hydrochloric acid 
(pH 2-3, 50ml) and the oily layer formed was extracted with, ethyl 
acetate . (,100ml) and the extract was dried (anhydrous sodium 
sulphate). The solvent was evaporated to leave a small volume 
of material. Light petroleum (b.p. 60-80°C) was added to 
precipitate the solid (1.2g) of m.p. 165-174°Co
•After recrystallisation, to a constant melting point, from methanol 
the product, Alclofenac-glycyl-glycine, (700mg) of m.p. 170-174°C, 
was obtained.
1H n.m.r. (dimethylsulphoxide):
3.42ppm, 2H, singlet, (CH2 ); 3.55ppm, 4H, two doublets, (CH2 ,
e g
CH )} 4.62ppm, 2H, multiplet, (CH ); 5.34ppm, 2H, multiplet,
1  c
(CH2 ); 6.1ppm, IH, multiplet, (CH^ ) j 7.23ppm, 3H, multiplet, 
a
(aromatic protons d) ? 8.21ppm, 2H, multiplet, (NH , NH, ) ;
f n
12.5ppm, IH, broad singlet (CCbH.).
£ D
The infrared soectrum showed strong absorotions at 3330cm 1, 
3240cm”1, 1730cm 1, 1650cm 1 (broad) , 1550cm \  150Qcm 1,
1430cm”1, 1270cm”1, 1250cm”1, 1230cm”1, 1220cm"1, 1060cm”1,
-1 -1 -1 -1 -1 -1 1010cm , 990cm , 890cm , 800cm , 690cm , 640cm
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C15H17N205C1 requires C,52.87; Hf5.03; N,8„22; 01,10.40%.
1 7  Alclofenac-p-riitrdpheriyl ester:
Alclofenac (4.3g) was dissolved in dry tetrahydrofuran (20ml).
To the solution was added_P_-nitrophenol (2.28g) in dry chloroform 
(30ml) o
DCC (4.1g) was then added and the whole was then stirred at 
room temperature overnight.
TLC analysis was then carried out. The sample separated into 
two fractions £ (R^  = 0.89) , Id (Rf = 0.72) . Fraction b was
identified as Alclofenac by use of a marker. Fraction £ was possbily 
the product.
DCU was filtered off. The volatile material was evaporated at 
reduced pressure. The solid residue was dissolved in chloroform 
(100ml). The chloroform solution was washed with saturated 
aqueous sodium bicarbonate solution (2 x 50ml) and then with 
water. The extract was dried (anhydrous sodim sulphate) and 
then decolorised with charcoal.
The solvent was evaporated at reduced pressure to leave a small 
volume of material. Light petroleum (b.p. 4P-60°C) was added to 
give the solid (2.0g) of m.p. 66-67°C.
After recrystallisation from diethyl ether the product,
Alclofenac-_P-nitrophenyl ester, (1.5g) of m.p. 66-69.5°C was 
obtained,
Found: C,52.67; H,5.00; N,8.20; 01,10.51*
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H n cm.r. spectrum (deuterochloroform):
3.80ppm, 2H, singlet, (CH )? 4061ppm, 2H, multiplet, (CH );
e c
5„53ppm, 2H, multiplet, (CH^  )? 6014ppm, 1H, (CH^ ) ? 6.9ppm,
a cJowVd\c_ ^ovAAga:
1H, doublet, (J = 8c25Hz), (CH ); 7„3ppm, 1H, (J = 2.3Hz,
/ \
8o25Hz), (CHg); 7.4ppm, doublet, 1H, (J =2.3Hz)? (CH^); 7.2ppm,
2H, doublet, (J = 9.2Hz), (CH , CH ); 8„2ppm, doublet,
ai  at
(J = 9.2Hz), (CH , CH ).
%
-1The infrared spectrum showed strong absorptions at 1750cm ,
1590cm-1, 1520cm"1, 1500cm"1, 1345cm"1, 1280cm"1, 1250cm"1, 
1230cm"1, 1210cm"1, 1120cm"1, 1060cm"1, 920cm"1, 865cm"1, 795cm"1
-- Found: C,58.84; H,3.89? N,4.28? Cl,10.23.
C.„H .N0-C1 requires C,58.71? H,4.06? N,4.03; Cl,10o19%.
1 /  1 4  Z>
18 Alclofenac-glycine methyl ester:
Alclofenac-£-nitrophenyl ester (3069g) was dissolved in chloroform 
(30ml). To the solution was added glycine methyl ester hydrochloride 
(lo5g) in dry chloroform (30ml) containing dry triethylamine (1.4ml), 
and the solution was stirred at 40°C for 4hr.
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fractions a (R_ = 0.85), b (R_ = 0.70). and c (R_ = 0). Fraction a — r — • r — f —•
was identified as the product Alclofenac-glycine methyl ester by 
use of a marker (previously prepared by the DCC method see p. 64) .
v l)
Fraction b was identified as P_-nitrophenol by use of a marker.
Fraction £ was identified as glycine methyl ester using a ninhydrin 
test.
The reaction mixture was washed with saturated aqueous sodium 
bicarbonate solution (2 x 50ml) and then with water (2 x 50ml).
It was dried (anhydrous sodium sulphate). After treating with 
charcoal the solvent was evaporated at reduced pressure to leave 
a small volume of material. Light petroleum (b.p. 60-80°C) was 
added to give the solid (2.0g) of m.p. 68-73°C. After recrystallisation 
from chloroform/light petroleum (b.p. 60~80°C) the product, 
Alclofenac-glycine methyl ester^(1.8g) of m.p. 70-73°C was obtained.
1The H n.m.r. spectrum (deuterochloroform) was identical to that 
obtained previously (see p. 65) .
The infrared spectrum was identical to that obtained previously 
(see p. 65). ■
1 9  (L)-Phenylalanine methyl ester hydrochloride:
(L)-Phenylalanine(45g) was suspended in dry methanol (200ml).
Dry hydrogen chloride gas was passed for lhr., whilst the flask 
was kept cool in an ice bath. After refluxing for lhr., dry 
hydrogen chloride gas was again passed for lhr., and refluxing 
was carried out again for lhr.
TLC analysis was then carried out. The sample separated into three
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The solvent was evaporated at.reduced pressure and a solid residue 
(41g) of m.p. 148-155°C was obtained. After recrystallisation from 
methanol/diethyl ether,the product, (L)-phenylalanine methyl ester 
hydrochloride (30g) of m.p. 158-.160°C was obtained.
79
Lit m.p. 162-164 C.
1H n.m.r. (deuterated water):
(D-.N—CH-C0-CHo )+c T  
3 I c 2 3d
a
3.3ppm, 2H, multiplet, (CH ); 3.85ppm, 3H, singlet, (CH );
b d^
4.4ppm, IH, triplet, (CHc); 7.9ppm, 5H, multiplet, (aromatic
protons d).
-1The infrared spectrum showed strong absorptions at 2600cm ,
2540cm"1, 2470cm"1, 2420cm"1, 1740cm"1, 1620cm"1 1580cm"1,
1495cm-1, 1290cm"1, 1240cm-1, 1210cm-1, 1145cm-1, 1115cm-1,
1080cm ri 1060cm ri 930 cm ri 905 cm ri 860cm ri 805cm ri 
740cm ri 700cm ri
20 (i) Alclofenac-(L)-phenylalanine methyl ester:
Alclofenac jD_-nitrophenyl ester (3.69g) was dissolved
/
in chloroform (30ml). To the solution (L)-phenylalanine 
methyl ester hydrochloride (4.32g) in dry chloroform 
(50ml) containing dry triethylamine (2.8ml) was added 
and the mixture was stirred at 40°C for 4hr.
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TLC analysis was then carried.out. The sample separated 
into three fractions £ (R^  = 0.80), b (Rf = 0.70) and 
£ (R^  = Q) . Fraction b_ was identified by use of a marker 
as p-nitrophenol<* Fraction £ was identified as 
(L)-phenylalanine methyl ester using a ninhydrin test. 
Fraction a. was possibly the product.
The reaction mixture was then washed with saturated 
aqueous sodium bicarbonate solution (2 x 50ml) , and 
then with water (2 x 50ml) . It was dried (anhydrous 
sodium sulphate). After treating with charcoal the 
solvent was evaporated at reduced pressure to leave 
a small volume of material. Light petroleum (b.p. 
80-100°C) was added? the solid (3o0g) of m.p. 65-70°C 
was precipitated.
After recrystallisation from chloroform/light petroleum 
(b.p. 80-100°C) the product, Alclofenac- (L) - phenylalanine 
methyl ester (2.4g) of m.p. 67-70°C was obtained.
1H n.m.r. (deuterochloroform) :
0CH—CH=CH i2 b 2 c a
3.05ppm, 2H, multiplet, (CH ) ? 3.44ppm, 2H, singlet,
h
(CH^  )f 3.71ppm, 3H, singlet, (CH^  )? 4.76ppm, 2H, multiplet.
j
e
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(CH )j 4.84ppm,.IH, multiplet, (CH ); 5.46ppm, 2H, 
c 9
multiplet, (,CH2 ) ; 5,8ppm,_ J.H, broap doublet, (NHf). ; 
a
6.12ppm, IH, multiplet, (CH^ ) ; 6.89ppm, 3H, multiplet, 
(aromatic protons d); 7.22ppm, 5H, multiplet, (aromatic 
protons i)„
The infrared spectrum showed strong absorptions at 
3240cm-1, 1745cm”1, 1645cm-1, 1550cm-1, 1500cm-1, 1250cm-1,' 
1160cm-1, 1060cm-1.
Found: C,64.95; H,5.50; N,3.65; Cl,9.09.
C21H22N°4C1 re<5uires C,65.03; H,5.72? N,3.61; Cl,9. 14%.
r 20° o[a]^  = -6.28
(ii) Alclofenac (8„46g) was dissolved in dry tetrahydrofuran 
(50nl). To the solution was added (L)-phenylalanine 
methyl ester hydrochloride (8.62g) in dry chloroform 
(50ml) .
DCC (8.24g) was added and the reaction mixture was stirred 
overnight at room temperature.
TLC analysis was then carried out. The sample separated 
into three fractions a. (Rf s. 0.80) , ib (R^  *= 0.72) and c_
(R^  = 0). Fraction b was identified as (L)-phenylalanine 
methyl ester using a ninhydrin test. Fraction a_ was 
identified as the product by use of a marker, Alclofenac-
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(L) -phenylalanine methyl ester (previously prepared by the 
ONP method s.ee p. 86) .
The volatile material was evaporated at reduced pressure.
The semi-solid residue was dissolved in chloroform (100ml). 
The chloroform solution was washed with dilute hydrochloric 
acid (0.5m , 2 x 100ml), saturated aqueous sodium bicarbonate 
solution (2 x 100ml), and finally with water (2 x 100ml) .
The extract was dried (anhydrous sodium sulphate) and 
concentrated to a small volume. Light petroleum (b.p. 
80-100°C) was added to give the solid (4.0g) of m.p.
66-70°C.
After recrystallisation from chloroform/light petroleum 
(b.p. 80-100°C) the product,
Alclofenac-(L)-phenylalanine methyl ester (3.7g) of 
m.p. 67-70°C was obtained.
1H n.m.r. spectrum (deuterochloroform) was identical to 
that obtained previously (see p.p. 87,88).
The infrared spectrum was identical to that obtained 
previously (see p. 88) .
[a]20 = - 5.29°
Alclofenac-(L)-phenylalanine;
(i) Alclofenac-(L)-Phenylalanine methyl ester (3.5g) was
suspended in acetone (70ml) to which was added aqueous
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sodium hydroxide (1M, 18ml) and.heated gently to effect 
a solution. The re action immixture was kept warm at 40 °C 
for 30 min.
TLC analysis was then carried out. The sample was a 
single fraction (Rf = 0.45).
After the solution had been cooled to 0°C the pH was adjusted 
to 2-3 using dilute hydrochloric acid (3M), and then extracted 
with ethyl acetate (50ml). The extract was dried (anhydrous) 
sodium sulphate) and the volatile material was evaporated 
at reduced pressure to give a small volume of material, 
light petroleum (b.p. 80-100°C) was added to precipitate 
the solid (2.4g) of m.p. 111-116°C„
After recrystallising from ethyl acetate/light petroleum 
(b.p. 80-100°C) the product,
Alclofenac-(L)-Phenylalanine (1.8g) of m.p. 114-116°C 
was obtained
1H n.m.r. (dimethylsulphoxide):
3.0ppm, 2H, distorted, doublet (J = 5.6Hz), (CH )f 3.30ppm,
h
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2H, singlet, (CH )? 4.53ppm,-3H, multiplet, (CH ,.CH ) ?
^  2 Qe c • p
5.4ppm, 2H, .multiplet., (CE^  1} 6.0ppm, 1H, multiplet,
a
(CH^ )} 7.01ppm, 3H, multiplet, (aromatic protons d);
7.22ppm, 5H, multiplet, (aromatic protons i); 8.37ppm,
1H, doublet, (J = 8.2Hz), (NH^ ) ? 12.73ppm, 1H, broad
(CO H ) .
 ^ D
The infrared spectrum showed strong absorptions at 
3260cm"1, 1720cm"1, 1655cm"1, 1600cm"1, 1540cm"1, 
1500cm”1, 1290cm”1, 1250cm"1, 1060cm"1, 1020cm"1,
995cm"1, 925cm"1 795cm"1, 700cm”1.
Found: C,64.01? H,5.30? N,3.69? Cl,9.53.
C20H20N°4C1 re<Tuires C/64.26? H,5.39? N,3.75; Cl,9.48%.
(ii) Alclofenac-(L)-phenylalanine:
Alclofenac (2.3g) was dissolved in dry tetrahydrofuran 
(10ml). To the solution was added CDI (1.62g) and the 
reaction mixture was stirred at room temperature for 
30 min.
(L)-Phenylalanine (1.64g) in aqueous sodium hydroxide 
(IM, 10.0ml) was added and the reaction mixture was 
stirred at room temperature for Ihr. until effervescence 
ceased.
TLC analysis was then carried out. The sample separated 
into three fractions a_ (R^  = 0.45) , b_ (R^  = 0.72) and £ 
(R^  = 0) . Fraction b_ was identified by use of a marker
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as Alclofenac. Fraction £ was identified as (L)-phenylalanine 
using a ninhydtin test. /.Fraction a_ was identified by use of 
a marker as Alclofenacr-(L)-phenylalanine [previously 
prepared by the hydrolysis of Alclofenac-(L)-phenylalanine methyl
*
ester see p. 89).
The reaction mixture was added to aqueous hydrochloric acid 
(1M, 50ml) . The oily layer was extracted with ethyl acetate 
(100ml) and the extract was dried (anhydrous sodium sulphate).
The solvent was evaporated at reduced pressure to leave a 
small volume of material. Light petroleum (b.p. 80-100°C) 
was added to give the solid (1.5g) of m.p. 112-116°C.
After recrystallisation from ethyl acetate/light petroleum 
(b.p. 80-100°C) the product, Alclofenac-(L)-phenylalanine 
of (0.6g) of m.p. U4-116°C was obtained.
The ri n.m.r. spectrum (dimethylsulphoxide) was identical 
to that obtained previously (see p.p. 90,91).
The infrared spectrum was identical to that obtained 
previously (see p. 91).
22 The attempted'preparation of Alclofenac-(L)-phenylalanyl-(L)- 
Phenylalanine methyl ester:
Alclofenac-(L)-phenylalanine (as prepared on p. 89) (1.87g).
was dissolved in dry tetrahydrofuran (10ml). To the solution 
was added (L)-phenylalanine methyl ester hydrochloride in dry 
chloroform (10ml) containing dry triethylamine (0.7ml).
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DCC.(l.Q2g) was added and the.reaction .mixture was stitred overnight.
TLC analysis was then carried.out. The sample separated into
three fractions a_ (R^  = 0.66) , b (R_^ = 0.45) and c_ (Rf = 0) „
Fraction !b was identified by use of a marker as Alclofenac-(L)-
phenylalanine. Fraction _c was identified as (L)-phenylalanine
methyl ester using a -ninhydrin test. Fraction a_ was possibly the 
product.
DCU was filtered off. The volatile material was removed at 
reduced pressure. The semi-solid residue was dissolved in 
chloroform (50ml). The chloroform solution was washed with 
dilute hydrochloric acid (0.5M, 2 x 20ml), saturated aqueous 
sodium bicarbonate solution (2 x 20ml), and finally with water 
(2 x 20ml). The extract was dried (anhydrous sodium sulphate)*
The solvent was evaporated to leave a small volume of material.
Light petroleum (b.p. 80-100°C) was added to give the solid 
(700mg) of m.p. 114-120°C.
After recrystallisation from chloroform/light petroeum (b.p.
80-100°C) the product,
Alclofenac-phenylalanyl-phenylalanine methyl ester (600mg) of 
m.p. 118-120°C was obtained.
H n.m.r. (deuterochloroform):
CL LLL .LL^gL .n ,, ~
c a
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2.96ppm, 4H, multiplet, (CH , CH . ) ; 3035ppm, 2H, singlet,
h +1
(CH2 ) ;■ 3,6^ppm, 3H, two singlet^, (.CH •) ? 4„7ppm, 4H, multiplet,
e n
(CH2 , CH , CH^ ) ; 5 «53ppm, 2H, multiplet, (CH2 )? 6.16ppm, 1H, 
c a
multiplet, (CH^ ) ? 7„0ppm, 15H, multiplet, (aromatic protons d,
aromatic protons i, aromatic protons m, NH , NH ) .
X JC
— 1The infrared spectrum showed strong absorptions at 3360cm ,
1745cm"1, 1645cm"1, 1545cm"1, 1500cm"1, 1255cm’1, 1060cm"1,
700cm 1.
Found: C,67.27; H,5.80? N,5.42? Cl,6.76.
C3OH31N205C1 re(5ui-res C/67.34? H,5.84? N,5.24; Cl,6.63%.
(ii) The preparation of Alclofenac-(L) -phenylalanyl-(L) -phenylalanine 
methyl ester was repeated at a lower temperature -5 to 0°C and 
the reaction mixture was worked up after 6hr.
1In the H n.m.r. spectrum the OCH^ signal still appeared as two
n
singlets.
23 Alclofenac-phenylalanyl-phenylalanine:
Alclofenac-phenylalanyl-phenylalanine methyl ester (as 
prepared on p. 92) (5.3g) was suspended in acetone (40ml) to
which was added aqueous sodium hydroxide (IM, 20.0ml) and the 
whole was heated to effect solution.
On TLC analysis the solution was found to contain a single 
substance (R^  = 0.41).
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After the solution had been cooled to 0°C the pH was adjusted to 2-3, 
using aqueous hydrochloric acid (3M) and the whole was extracted with ethyl 
acetate (80ml). The extract was dried (anhydrous sodium sulphate) 
and the solvent was evaporated at reduced pressure to leave a 
smaTl volume of material. Light petroleum (b.p. 80-100°C) was 
added to precipitate the solid (3„5g) of m.p. 180-186°C.
After recrystallisation from ethyl acetate/light petroleum 
(b.p. 80-100°C) the product,
Alclofenac-phenalalany1-phenylalanine (2.7g) of m.p. 183-186°C 
was obtained.
■H n.m.r. spectrum (dimethylsulphoxide):
CH-— CO-NH - CH-C0-NHtCH—CO„H 2 f L.h 2 n
2
OCH— CH=CH0 z b z c a
3.0ppm, 4H, multiplet, (CH^  , CH2 )j 3»29ppm, 2H, singlet, (CH2 );
g 1 e
4.8ppm, 4H, multiplet, (CH2 , CH^, CH^); 5.4ppm, 2H, multiplet,
c
(CH2 ); 6.0ppm, IH, multiplet, (CH^); 7.2ppm, 13H, multiplet, 
a
(aromatic protons d, aromatic protons i, aromatic protons m); 
8.4ppm, 2H, broad multiplet, (NH^ , NH_,).
(The carboxyl proton was broad, in the range 7.0-8.5 ppm)'.
-1The infrared spectrum showed strong absorptions at 3240cm ., 
1725cm-1, 1625cm-1, 1545cm-1, 1495cm”1, 1250cm”1, 1200cm”1,
-1 -11060cm , 990cm
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Found: C/66.99? H,5.47? N,5.32?. 01,6.85.
C29H29N2°5C1 re<3.uires c,66. 85? H,5 .61? N,5 ,38 ? Cl,6.80%.
These preparations (20(ii) to 23) of phenylalanyl peptides of 
Alclofenac were repeated by the DCC method using (DL) - 
phenylalanine methyl ester hydrochloride.
24 (i) Alclofenac-(DL)—phenylalanine methyl ester:
The product had a m.p. 69-72.5°C. The *H n.m.r. spectrum 
(deuterochloroform) was identical to that obtained 
previously (see p.p. 87,88).
The infrared spectrum was identical to that obtained 
previously (see p. 88) .
Found:-C,65. 12? H,5.96? N,3.83? Cl,8.90.
C21H22N04C1 squires C,65.03? H,5.72? N,3.61, Cl,9.14%.
(ii) Alclofenac-(DL)-phenylalanine:
rY 1The product had a m.p. of 110-113 C. The H n.m.r. 
spectrum (dimethylsulphoxide) was identical to that 
obtained previously (see p.p. 90,91)
The infrared spectrum was identical to that obtained 
previously (see p. 91).
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C20H20N04C1.requires C,64.26; H.,5.39; N, 3.75; Cl,9.48%.
(iii) Alclofenac-(DL)--Phenylalanyl-(DL)-phenylalanine methyl 
ester:
The product had an m.p. of 120-123 C. The H n.m.r. 
spectrum (deuterochloroform) was identical to that 
obtained previously (see p.p. 93,94).
The infrared spectrum was identical to that obtained 
previously (see p. 94).
Found: C,67.16? H,6.06? N,5.45; Cl,6.85.
C H N 0 Cl requires C,67.34; H,5.84; N,5.24; Cl,6.63%.30 31 2 5
(iTT) Alclofenac- (DL) -phenylalanyl- (DL) -phenylalanine:
The product had an m.p. of 157-160°C.
1The H n.m.r. spectrum (dimethylsulphoxide) was identical 
to that obtained previously (see p. 95) .
The infrared spectrum was identical to that obtained 
previously (see p. 95).
Found: C,66.45; H,5.82; N,5.52? Cl,6.72.
C29H29N2°5C1 recIuires C,66.85; H,5.61; N,5.38; Cl,6.80%.
Found: 0,64.13; H,5.34; N,3.-84? Cl,9.05.
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Alclofenac-(DL)-phenylalanyi-(DL)-phenylalanine (1.20g) was 
dissolved in dry tetrahydrofuran . (10ml). To the solution was 
added glycine methyl ester hydrochloride (0.25g) in dry 
chloroform (10ml) containing dry triethy1amine (0.28ml).
DCC (0.41g) was added and the reaction mixture was stirred 
overnight at room temperature. DCU was then filtered off.
TLC analysis was then carried out. The sample separated into
three fractions. a (R_ = 0.54) , b (R_ = 0.41) and c ( R = 0) .—  1 —  t —  f
Fraction _c was identified as glycine methyl ester using a 
ninhydrin test.
Fraction L was identified as Alclofenac-(DL)-phenylalanyl-(DL)- 
phenylalanine by use of a marker. Fraction £ was possibly the 
product.
The volatile material was evaporated at reduced pressure and 
the semi-solid residue was dissolved in chloroform (50ml). The 
chloroform solution was washed with dilute hydrochloric acid 
(pH 2-3, 2 x 50ml), saturated aqueous sodium bicarbonate 
(2 x 50ml), and finally with water (2 x 50ml) . The extract was
dried,(anhydrous sodium sulphate), and concentrated to a small
volume. Light petroleum (b.p. 80-100°C) was added to give a 
solid (lOOmg) of m.p. 73-80°C.
After recrystallisation from chloroform/light petroleum (b.p. 
40-60°C) the product,
25 Alclofenac-(DL)-phenylalanyl-(DL)-phbnylalany1-glycine
methyl ester:
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Alclofenac-(DL)-phenylalanyl-(DL)-phenylalany1-glycine methyl 
ester, (80mg), of m.p. 77-81°C was obtained.
H n.m.r. spectrum (deuterochloroform) :
CH-CO-NH—  CH — CO-NH-r— CH-C0-NH-—CH I 2e f  ^ V k n , 2
CP2
CH3
x x ,  x x
nCH-CH=CH_ mO 2 2
c a
2.99ppm, 4H, multiplet, (CH , CH )? 3.34ppm, 2H, two singlets,
h 1
(CH2 )} 3.69ppm, 3H, two singlets, (OCH^ )r 3.93ppm, 2H, multiplet, 
e p
(CH2 ); 4.37ppm, IH, broad doublet, (NH) ; 4.6ppm, multiplet, 
o
4H, (OCH2 , CH , CH^); 5.41ppm, multiplet, 2H, (CH ); 6.3ppm, 
c g . a
multiplet, 2H, (CH^ , NH)? 7.0ppm, multiplet, 14H, (aromatic protons
d; aromatic protons i, aromatic protons m, NH). (Precise assign­
ments for the NH groups were not possible) .
The infrared spectrum showed strong absorptions at 3260cm ri
3330cm”1, 1745cm”ri 1630cm 1, 1495cm ri 1250cm ri 1060cm”1,-1 -1 -1 -1 -1
985cm ri 920cm ri 795cm 1
Found: C,64.58; H,5.76; N,7.29? Cl,5.85.
C^H-^N 0 Cl requires C,64.91; H,5.79; N,7.10; Cl,5.98%
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Monitored hydrolysis of Alclofenac-glycine hinder acidic conditions
AlcTofenac-glycine (l.Og) was- dissolved in methanol (10ml). To 
the solution was added aqueous hydrochloric acid (pH 1.5, 10.0ml).
After allowing to stand at room temperature TLC analysis was 
carried out. The sample gave but one spot (R^ = 0.50). It was 
identified as Alclofenac-glycine by use of a marker.
The mixture was warmed to 37°C and TLC analysis was carried out every 
15min., for 4hr. .Each sample gave but one spot (R^  = 0.50).
No hydrolysis of Alclofenac-glycine under these acidic conditions 
to form Alclofenac and glycine could be detected during a 4hr. run.
3-Chloro-4-n-propoxyphenylacetylglycine methyl ester;
Alclofenac-glycine methyl ester (3.0g) was dissolved in absolute 
ethanol (100ml),'and Adams catalyst (20mg) was added.
Hydrogenation was carried out in an atmospheric pressure 
hydrogenator for 5hr. until hydrogen (310ml) had been taken up.
The catalyst was removed from the reaction mixture by filtration, 
the solvent was then evaporated at reduced pressure^ and to the 
residue was added light petroleum (b.p. 40-60°C); a solid product 
(600mg) of m.p. 76-80°C was obtained.
After recrystallisation from chloroform/light petroleum (b.p.
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3-Ch,Iofo-4-n-propoxyphenylacetylglycine methyl ester (200mg) had 
m.p. of 79-82°C.
1H n.m.r. spectrum (deuterochloroform):
40-60°C), the product,
1.06ppm, 3H, triplet, (J = 7.3Hz), (CH^ )? 1.85ppm, 2H, sextet,
a
(J = 7.3Hz), (CH2) f 3.52ppm, 2H, singlet, (CH )? 3.73ppm, 3H, 
b e
singlet, (OCH^ )? 4.03ppm, 4H, multiplet, (0CH2 , CH2 )? 6.06ppm 
h e g
IH, (broad) , (NH^ ) ? 7.2ppm, 3H, multiplet, (aromatic protons d)
The infrared spectrum showed strong absorptions at 3260cm”1, 
1732cm"1, i640cm”1, 1550cm”1, 1495cm”1, 1260cm”1, 1220cm"1, 
1160cm 1, 1050cm \  975cm 880cm 1, 810cm 1.
Found: C,55.86; H,5.91? N,4.61? Cl,11.88.
C14H18N°4C1 requires c /56-09? H,6.05 ? N,4.67? Cl,11.83%.
3 (a) 3-Chloro-4-n-propoxyphenylacetyiglycine:
3-Chloro-4-n-propoxyphenylacetylglycine methyl ester was 
prepared as before (see p. 100) , but on this occasion 
the oily residue obtained after the work-up procedure was 
not treated with, light petroleum (b.p. 40-60°C). It was 
suspended in acetone (80ml) and to it was added aqueous 
sodium hydroxide . (1M, 20.0ml) . The mixture was warmed, at
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40°C for 30 min., to effect a solution.
After cooling to 0°C, the pH, was reduced to 2-3, using aqueous 
hydrochloric acid (,3M). , and the whole was extracted with ethyl 
acetate (100ml). The extract was dried (anhydrous sodium 
sulphate) and the volatile material was evaporated at reduced 
pressure to give a small volume of material. Light petroleum 
(b.p. 40-60°C) was added to precipitate the solid (l.Og) of 
m.p. 105-110°C.
After recrystallisation from ethyl acetate/light.petroleum
(b.p. 40-60°C), the product, 3-Chloro-4-n-propoxyphenylacetylglycine
(600mg) of m.p. 110-112°C was obtained.
1H n.m.r. spectrum (dimethylsulphoxide) ;
l.Oppm, 3H, triplet, (J = 7.3Hz), (CH^ ); 1.74ppm, 2H,
a
sextet, (7.3HZ), (CH2 ); 3.35ppm, 2H, singlet, (CH2 )»
b e
3.74ppm, 2H, doublet, (J = 5.GHz), (CH^  ); 3.97ppm, 2H,
g
triplet, (J = 6.3Hz) (CH2 ); 7.1ppm, 3H, multiplet,
c
(aromatic protons d) ; 8.3ppm, 1H, broad triplet, (NH^ ) j 
12.0ppm, 1H broad singlet, (CO^H^) .
-IThe infrared spectrum showed strong absorptions at 3335cm ,
1715cm"1, 1610cm"1, 1520cm"1, 1500cm"1, 1345cm"1,
1310cm"1, 1285cm"1, 1260cm"1, 1230cm"1, 1060cm"1, 985cm"1,
-1 -1 -1925cm , 870cm , 820cm
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Found: C,54.73? H,5.38? N,5.23; Cl,12.68-
C13H16N04C1 requires'C/54.64; H,5.64? N,4.90? Cl,12.43%.
(b) Alclofenac-glycine (2.0g) was dissolved in absolute ethanol
it (100ml), and Adams catalyst (20mg) was added.
Hydrogenation was carried out in an atmospheric pressure 
hydrogenator for 5hr. until hydrogen (300ml) had been taken 
up. The catalyst was removed from the reaction mixture by 
filtration, the solvent was then evaporated at reduced 
pressure and to the residue was added light petroleum 
(b.p. 40-60°C); a solid product (l.Og) of m.p. 104-110°C 
was obtained.
After recrystallisation from chloroform/light petroleum 
(b.p. 40-60°C), the product,
3-Chloro-4-n-propoxyphenylacetylglycine (600mg) had m.p.
110-112°C.
1H n.m.r spectrum (dimethyIsulphoxide) was identical to that 
obtained previously (see p. 102) .
The infrared spectrum was identical to that obtained 
previously (see p.102).
Found: C,54.40; H,5.92; N,4.78.
Cl3H16Nd4Cl C,54.64; H,5.64? N,4.90*
SPECIMEN INFRARED AND ri n.m.r. SPECTRA
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PART III
DISCUSSION
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The concept that the coupling of amino acids or their derivatives 
to acetylsalicylic acid, Aspirin,or to 4-allyloxy-3-chlorophenylacetic 
acid, Alclofenac, might lead to compounds of pharmacological interest 
was introduced in Part I.
In order to gain some experience in the field, it was decided to
attempt the preparation of some derivatives of acetylsalicylic acid.
Acetylsalicyloyl-(L)-alanine has been prepared by Fromming and 
40Vollenberg by the use of MCA method. Further, a tripeptide containing
the D-alanyl residue has been found to show useful pharmacological
80properties. It was decided to work with (DL)-alanine and to attempt 
the preparation of acetylsalicyloyl-(DL)-alanine by this mixed 
anhydride method; if either the D- form or the L- form of this product 
was bioactive pharmacological tests would, perhaps, indicate some 
bioactivity in the racemate.
40Fromming and Vollenberg reported that from 18.Og of acetylsalicylic 
acid they were able to obtain the product in 60% yield. Following 
their procedure and using the sodium salt of (DL)-alanine the 
preparation of acetylsalicyloyl-(DL)-alanine was attempted.
Although the product was obtained the yield was low (6%). The 
compound had a melting point 118-120°C.
40Fromming and Vollenberg reported a melting point for the 
L- compound to be 122°C.
The 1H n.m.r. spectrum, the infrared spectrum,and the combustion 
analytical figures were in accord with the expected structure:
(see p. 43):-
The infrared spectrum showed clear evidence of absorptions
-1associated with NH stretch at 3400cm, and carbonyl absorptions 
at 1750cm"1 (CH3C0.0) 1715cm"1 (C02H) , and 1640cm"1 (CO.NH).
Since the product yield was disappointing various different 
reaction conditions were tried in order to improve the yield 
(see p. 44). it was found possible to increase the product 
yield to r*20% fromr*?6% using a longer reaction time (6hr. instead 
of 3hr.), and a higher temperature (0°C instead of -5°C).
TLC analysis of the reaction mixture after aminolysis showed that 
in addition to the starting materials, identified by use of markers, 
it contained two other fractions apart from the expected product.
Salicyloyl-(DL)-alanine was prepared and used as a marker as was 
salicylic acid. One of the fractions was identified as salicyloyl- 
(DL)-alanine; salicylic acid was not present. The unidentified 
fraction was perhaps the activated intermediate, the mixed anhydride, 
acetylsalicyloyl ethyl carbonate, or a decomposition product.
The synthesis of acetylsalicyloyl ethyl carbonate was effected; 
it was an oil which was not subjected to combustion analysis.
The H n.m.r. spectrum was in accord with the proposed structure 
(see p. 46):-
CO- 0- C0-0Et
0.C0.CH,
13 si <In addition, the C n.m.r. spectrum showed four signals of interest
(see p. 47 ) in the range for the carbonyl carbon atoms. Three of these
can be assigned to the three carbonyl groups and the other to the
aromatic carbon atom to which the acetoxy group was bonded.
13(Signals associated with carbonyl groups in C n.m.r. spectroscopy
81
occur in the range (150-220ppm) .
The infrared spectrum showed strong anhydridic carbonyl absorptions
-1 -1at 1740cm - 1820cm
Further, TLC analysis of the reaction mixture using acetylsalicyloyl 
ethyl carbonate as the marker showed that it was indeed present. The 
aminolysis step was not going to completion; due, perhaps, to the mixed 
anhydride intermediate being relatively unreactive.
Since the acetylsalicyloyl-(DL)-alanine could be obtained by this 
MCA method it was considered that the dipeptide derivative, 
acetylsalicyloyl-(DL)-alanyl-(DL)-alanine, might also be obtained 
by coupling the sodium salt of (DL)-alanine with the activated 
acetylsalicyloyl-(DL)-alanine. Furthermore it was also known 
from a literature survey that the repetition of this MCA process,
(REMA) to produce a long chain peptide had been done successfully. 
This route was tried in order to prepare acetylsalicyloyl-(DL)- 
alanyl-/DL)-alanine. (see page 47).
82
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TLC analysis of the reaction product after the work-up procedure 
indicated that it was a mixture of five fractions, and that in 
addition to the starting material, acetylsalicyloyl-(DL)-alanine, 
and salicyloyl-(DL)-alanine there were three other fractions. One 
may‘have been the desired product, another could have been the 
anhydride intermediate (Rf = 0.80).
The preparation was repeated using a longer reaction time (8hr.); 
there was still some material of R^ = 0.80 and some unreacted 
(DL)-alanine as shown by the TLC analysis of the reaction mixture; 
this route did not appear to be promising.
Difficulties in the purification may, perhaps, be relieved by the 
use of an amino ester in place of the sodium salt in that the 
product, a dipeptide ester derivative of Aspirin, could perhaps 
be separated from the acidic starting material, acetylsalicyloyl- 
(DL)-alanine, by washing a solution of the reaction product in 
an organic solvent with the saturated aqueous sodium bicarbonate 
solution. Furthermore, the use of an aqueous-organic solvent 
system during the reaction could be avoided since the amino esters 
unlike the amino acids are soluble in organic solvents. By this 
approach and using, perhaps^ a different coupling procedure, 
involving the use of N,N riaicyclohexyIcarbodiinri.de, DCC, coupling 
could perhaps be effected more efficiently. Anhydrous conditions 
facilitate the coupling reaction. Since there are no solubility 
difficulties with the ester, both the activation and the aminolysis 
step can be carried out in a dry organic solvent. Side reactions 
such as the hydrolysis of the acetoxy group, OCOCH^, are thus 
avoided.
Amino acid esters can cyclise to form dike top iperazines. This is 
particularly true of the methyl or ethyl esters. However, the 
methyl or ethyl ester hydrochlorides are stable,. They can readily 
be prepared and they can be stored. The free amino esters can be 
generated in situ by adding an equivalent quantity of a base when 
appropriate.
(DL)-alanine methyl ester hydrochloride was prepared.
1The H n.m.r. spectrum and the infrared spectrum were in accord 
with the structure below (see p. 49)
<+) (-)(NH-CH-CO ,-CH ') Cl
c h3
(+)
(Signals associated with the NH^ group were not observed due to 
the rapid exchange in the solvent D^O).
(+)
The infrared spectrum showed evidence for NH^ absorptions at
-1 -1 -1 -12720cm , 2670cm , 2600cm , 2530cm , and the presence of an
-1ester carbonyl group at 1750cm
78The melting point was in agreement with that in the literature.
The preparation of acetylsalicyloyl-(DL)-alanyl-(DL)-alanine 
methyl ester was attempted using the DCC method. Acetylsalicyloyl- 
(DL)-alanine was coupled with (DL)-alanine methyl ester generated 
in situ from its ester hydrochloride in acetonitrile solution.
The by-product of this reaction, dicyclohexylurea, DCU, was 
filtered off, and the filtrate was worked up as previously described 
for the MCA method.
The chloroform extract obtained after the work-up procedure was 
subjected to TLC analysis. No starting materials were now present; 
the product was a mixture of two fractions (Rf = 0.57 and Rf = 0.63). 
On treatment with light petroleum the product did not solidify; 
further purification was not attempted.
The preparation was repeated using methylene chloride as the solvent; 
the product had similar properties to those obtained before.
The preparation was then attempted by the MCA method which had been 
used earlier. This time, however, instead of using the sodium salt 
of (DL)-alanine (DL)-alanine methyl ester was used in order to 
ease the difficulties in purification. The product was washed with 
light petroleum to remove any mixed anhydride? the residue did not 
solidify.
TLC analysis of this oil showed it to be a mixture of two fractions 
analogous to those obtained using the DCC coupling method.
1The H n.m.r. spectrum was in broad agreement with the structure 
given below (see p. 53)
except that the signals associated with the methyl groups were more 
complex than ejected. Signals associated with the ester methyl 
group appeared as two singlets and the signals associated with the 
two methyl groups of the two alanyl residues appeared as multiplets.
C0..NH.CH (CH ) .CO.NH.CH (CH ).C0 .CHD Z ,j
0. CO. CH3
1
This multiplicity in the H n.m.r. signal and the presence of two
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a mixture of two diasteroisomerides. This observation is in accord
8 3with that reported by Halpern et at who have studied the spectra 
of.a series of alanyl peptides. They reported that there is a 
small change in the chemical shifts of methyl resonances between 
L,L- and L,D-alanyl dipeptides.
Although no solid product was obtained some experience had been 
obtained at coupling amino acid residues on to a carboxylic acid 
and it was decided at this stage to concentrate further efforts 
to produce peptide derivatives of Alclofenac.
fractions as shown by the TLC analysis suggest that product was
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■anfflfc PV^ CA~°
Alclofenac (supplied by Berk Pharmaceuticals Ltd) had a melting
6
point close to the literature melting point.
The H n.m.r. spectrum and the infrared spectrum were in accord 
with the structure (see p. 54 )
The infrared spectrum showed evidence for the presence of absorptions
-1associated with bonded OH stretch (CO^ H) at 2900cm , acidic carbonyl
absorptions and vinyl absorptions (CHrCH^) at 1640^17.20 cm fobroad), 
aromatic skeletal stretching modes at 1500 cm \  Ar-O-CH^ deformations 
at 1260 cm fo. aromatic CH out of planfi deformations at 795 cm \
720 cm .
Earlier (see p.p. 42, 123) it was shown that the MCA method of coupling 
led to the preparation of a mono- alanyl derivative of Aspirin, 
acetylsalicyloyl-(DL)-alanine, and although the yield was low, the 
compound obtained was satisfactorily characterised. It was noted 
also that the purification difficulties could be eased if an ester 
of (DL)-alanine was used instead of the sodium salt. It was 
therefore decided to attempt the preparation of Alclofenac-(DL)- 
alanine methyl ester by this MCA method, using (DL)-alanine methyl 
ester which was generated in situ from its ester hydrochloride.
TLC analysis of the reaction mixture after the activation step 
revealed it contained a mixture of two fractions one of which
- 131 -
was identified as Alclofenac (by use of a marker) R = 0.72.' f
The other was possibly, 4-allyloxy-3-chlorophenylacetyl 
ethyl carbonate, i.e.. a mixed anhydride by analogy with the mixed 
anhydride obtained when working with Aspirin*, this too appeared on the 
TLC chromatogram at a higher R^ value (0.91) compared with the 
acidic starting material, Aspirin.
TLC analysis of the product obtained after the aminolysis step 
showed that in addition to the starting materials two other 
fractions, one at R^ = 0.91, (which also appeared at the activation 
step and was thought to be a mixed anhydride of Alclofenac) , and 
another, at R^ = 0.65, were present; the latter was possibly the 
product.
After the work-up procedure, the residue was treated with light 
petroleum; a solid product separated which was filtered off and the 
filtrate was concentrated to leave a gummy residue. Both materials 
were then examined. The gum was found to be a mixed anhydride of 
Alclofenac, 4-allyloxy-3-chlorophenylacetyl ethyl carbonate.
\The H n.m.r. was in accord with the proposed structure (see p.p.56,57)
13In addition, the C n.m.r. spectrum showed the presence of two
82
signals in the region associated with carbonyl absorptions; three 
might be expected since the carbon atom to which, the allyloxy group 
is attached is expected to give a signal in this range (see p.71 ) .
The infrared spectrum, however, showed clear evidence for the
- 132 -
presence of strong anhydridic carbonyl absorptions at 182Q^-1735cm"i.
Combustion analyses on this activated intermediate were not obtained.
The solid product obtained was found to be the required compound, 
Alclofenac-(DL)-alanine-methyl ester.
1The H n.m.rQ spectrum and the infrared spectrum were both in 
accord with the expected structure (see p.57)
The infrared spectrum showed clear evidence for the presence of
-1absorptions associated with NH stretch at 3260cm , and carbonyl
-1 -1 groups at 1755cm (CC^.CH^) and 1610cm (-C0.NH-) .
The crude solid product was obtained in low yield (~-3.0%) . 
Attempts were made to improve the product yield by employing 
different reaction conditions, such as a longer reaction time, 
gentle warming at the aminolysis stage etc. There was no 
improvement in the product yield. Once again, the same problem 
as in the Aspirin work (see p.p.124,125) was encountered, the 
aminolysis step was not going to completion due, perhaps, to 
the mixed anhydride intermediate being relatively unreactive.
In view of the lack of success using the MCA method, the DCC 
method was then used in an attempt to prepare this compound.
The crude product was obtained' in ~30% yield,. After purification
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the required product was obtained (.23% yield); it gaye satisfactory 
combustion analys.es. (see p. 59) .
1The H n.m.r. and the infrared spectra were similar to those obtained 
previously, (see p. 57) .
From a literature survey it was known that the saponification of
peptide esters could be effected without the cleavage of the peptide 
84
bonds. Maclaren reports the conditions used in the saponification 
of N-blocked peptide esters. This procedure was applied to 
Alclofenac-(DL)-alanine methyl ester. The free acid, Alclofenac- 
(DL)-alanine, was obtained in -'-90% yield; it was a single substance 
as shown by TLC analysis. After purification the product, which 
was obtained in ~80% yield, gave satisfactory combustion analyses.
1 . . .  - 
The H n.m.r., the infrared spectra, and the combustion analyses were in
accord with the proposed structure (see p. 60) :-
The H n.m.r. spectrum showed no indications of a signal 
associated with a CH^O.CQ- methyl group? the presence of a broad 
singlet due to carboxyl proton signal at 12.5ppm was observed.
The infrared spectrum showed clear evidence for the presence of
absorptions associated with NH stretch at 3290cm 1, and a
carboxylic acid carbonyl group and an amide carbonyl group 
-1
at 1675cm
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The evidence showed that ester' hydrolysis had occurred without the 
cleavage of the amide bond.
A satisfactory synthetic route for coupling an amino acid to 
Alclofenac by coupling first the amino-ester and then hydrolysing 
the product to give the Alclofenac-amino acid derivative had 
now been established. It was considered that perhaps another 
amino acid ester could be coupled to such a mono-derivative to 
give an Alclofenac-dipeptide ester and thence Alclofenac-tripeptide 
derivatives could be prepared.
Alclofenac + amino ester Alclofenac-amino ester
DCC
amino ester
(i) saponification 
(ii) acidification
Alclofenac-dipeptide ester <£- Alclofenac-amino acid
DCC
(i) saponification
(ii) acidification
Alclofenac-dipeptide (free acid form) etc.
Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester, the first model 
dipeptide ester derivative of Alclofenac,was synthesised in this 
way.
The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the expected structure 
(see p.p. 61,62)
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.NH.CH(CH3).C0.NH.CH(CH3),C02CH3 
.CH2«,CH:CH2
Just as was the case with the dipeptide derivative of Aspirin, 
acetylsalicyloyl-(DL)-alanyl-(DL)-alanine methyl ester, the
iH n.m.r. signals associated with the methyl groups were more 
complex than anticipated. The ester methyl group signal appeared 
as two singlets and the signals associated with the two methyl 
groups of the two alanyl residues appeared as two multiplets.
As was explained earlier on p.p. 128,129, the multiplicity in these 
signals was due to the fact that the product was a mixture of two 
diasteroisomerides.
The infrared spectrum showed clear evidence for absorptions
-1associated with the NH stretches at 3270cm , carbonyl absorptions
-1 -1/at 1745cm (C02.CH3) , and at 1640cm Q-C0.NH-) , and also vinyl
absorptions (CH:CH2)^.« The crude product was obtained in ~ 50% yield 
from the starting material, Alclofenac-(DL)-alanine. After 
purification the product was obtained in a pure state in ~ 25% yield ; 
it gave satisfactory combustion analyses.
This route to the synthesis of peptide derivatives of Alclofenac 
appeared to be satisfactory in giving the products in sufficient 
quantities for pharmacological testing. It was therefore decided 
to use this synthetic route wherever possible to prepare further 
peptide derivatives of Alclofenac.
man and monkeys it conjugates with glycine to form Alclofenac-glycine.
Although studies show that the drug is excreted in this forn it
was felt that pharmacological tests on Alclofenac-glycine derivatives
might be of interest. Both Alclofenac-glycine ethyl ester and the
methyl ester were synthesised by the DCC method. The latter was
then hydrolysed to give Alclofenac-glycine.
1All these compounds were characterised. In all cases the H n.m.r. 
spectrum, the infrared spectrum and the combustion analytical figures 
were in accord with the expected structures (see p.p. 62,63,64,65,66).
The infrared spectrum of Alclofenac-glycinfc ethyl ester showed
_  ^
evidence for carbonyl absorptions at 1750 cm (-C0„CnH_), and erf:Z Z D
1650 cm 1 ^ (-CO. NH-) , and vinyl absorptions (CH*CH^7) that of Alclo­
fenac-glycine methyl ester showed carbonyl absorptions at 1745 cm 1 
(-CO^.CH^), and at 1645 cm 1 ^ (-CO,NH~), and vinyl absorptions (CHICK^ 
that of Alclofenac-glycine showed evidence for carbonyl absorptions
1 ^ (—C0.NH-) ,
)
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85Studies have revealed that when Alclofenac is metabolised in
-1at 1720 cm (-C02H), and^l645 cm [ (-C0.NH-)  and vinyl absorptions
(CH:CH2)
Alclofenac glycine methyl ester was also prepared by an activated
ester method, ONP. The activated intermediates prepared so far
73-75could not be isolated as crystalline solids. It was known from
a literature survey that esters of p-nitrophenol could be so obtained. 
Such an activated derivative of Alclofenac, Alclofenac-p-nitrophenyl 
ester, was prepared. It was a crystalline compound which was fully 
characterised.
1The H n.m.r. spectrum, the infrared spectrum and the combustion 
analytical figures were all in accord with the expected structure, 
(see p. 84) :-
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0oCH2.CH:CH2
The infrared spectrum showed clear evidence for the absorptions
-1associated with the carbonyl group at 1750cm j and the nitro
-1 -1 group at 1590cm and 1345cm
The preparation of Alclofenac-glycine methyl ester was attempted 
using the ONP method. Alclofenac-p-nitrophenyl ester was 
aminolysed at 40°C using glycine methyl ester generated in situ 
from its ester hydrochloride in dry chloroform.
TLC analysis of the reaction mixture after 4hr. revealed that it 
contained a mixture of three fractions. These were identified as 
the required product, £-nitrophenol, and glycine methyl ester.
After the work-up procedure, involving washing the organic layer 
with saturated aqueous sodium bicarbonate solution, water, drying 
followed by a charcoal treatment, the solid product, Alclofenac- 
glycine methyl ester was obtained. The product was identical to 
that obtained by the DCC method.
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It is known that some histidyl peptides have sedative properties.
It was considered that the preparations of some histidyl derivatives 
of Alclofenac might be of interest.
The first derivative, Alclofenac-histidine methyl ester, was
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prepared, by use of the DCC method. To generate the free ester 
in situ • .2 . equivalents of the ba,se trie thy 1 amine were added to 
(L)-histidine methyl ester dihydrochloride during the coupling
procedure.
«
A different TLC system had to be developed to follow the course 
of this particular reaction. Although silica gel plates (SG254) 
were again used it was found necessary to modify the solvent 
system (see p. 67).
Owing to the basic nature of the imidazole ring of the histidyl 
component a different pH, (pH 4.6), was used at the washing 
operation during the work-up procedure.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the expected structure, 
(see p. 68)
0CH2.CH:CH2
The infrared spectrum showed evidence for absorptions associated
-1 -1 with the NH stretches at 3180cm , carbonyl absorption at 1740cm
-1/(-C02CH3) andN1650cm (/-C0.NH-), and also vinyl absorptions (CH:CH2
Although (L)-histidine methyl ester was coupled to Alclofenac this 
does not mean that the product was Alclofenac-(L)-histidine methyl 
ester since some racemisation could have occurred. During the 
coupling reaction basic conditions were employed; triethylamine
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was present and furthermore the imidazole ring itself has some
basic qualities. Race.misation.is known to occur at room temperature
87r' " >?88
in the DCC method of coupling; it is known to be base catalysed.
f2 f2
C=0 c=0
HN 0 HN/ 0I /r I //R t-CH-C. __________  \ Rr—C-C
1 ■ \  i i * 1 (-> >
(+)(optically active) BH
X = activating group
(negative substituent)
+c=o
HN n
B; = a base R-C-C*1 J xX
H
(racemic)
2 oThe specific rotation of this compound was measured [ct] == -11.58°. 
and is reported as a physical constant for it; it may not be that 
of the optically pure compound.
Some experience at coupling histidyl residue to the carboxyl 
group of Alclofenac had now been gained, and attempts to prepare 
other histidine- containing derivatives of Alclofenac were now made.
The preparation of Alclofenac-glycyl-(L)-histidine methyl ester 
was then attempted using the DCC coupling method.
TLC analysis of the reaction mixture revealed that apart from the 
starting materials two other fractions were present.
After a work-up procedure (see p.p. 69,70) the solid product
1isolated was not found to be the required product. Its H n.m.r.
spectrum, and the comhustion' analytical figures were in accord with 
either of the two proposed isomeric structures, I and II, which 
would be expected to have similar ri n.m.r. spectra (see p. 70) .
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(I) N-(Alclofenac-glycyl)-dicyclohexylurea.
OR
(II) O-(Alclofenac-glycyl)-dicyclohexylurea.
Attempts have been made to resolve this problem.
13The C n.m.r. spectrum showed four signals of interest at 
171.4, 168.2, 153.4, and at 152.4ppm. Assignments from tables and 
from model compounds suggest that there are only small diagnostic
differences between the two forms I and II.
Y—CO.N.CO.NH N
m n -CO. 0. C
y lxQQ 'NHm= 161.5-168.5ppm
89 90
n= 151.1-155.3ppm y =o-*168ppm
x =~,155ppm- ''~158ppm
'V-C0.NH- C -O.CH1 / v 3
92 9 3
1 = 160-180ppm v = 159.4ppm
89,91
- 141 -
The infrared spectrum (see p* 70) , showed three strong signals in the
-1region associated with double bond stretching vibrations at 1715cm ,
_1 -l1665cm and 1640cm . One would expect three amide carbonyl
absorptions if the compound had structure I* however, if the
ft
compound had structure II one would expect two amide carbonyl
absorptions and one ester carbonyl absorption. Clearly there
are two amide carbonyls at 1665cm 1 and at 1640cm 1. The
-1carbonyl absorption at 1715cm is at a higher wave number than
94that expected for the amide group, but at a lower wave number
95than that expected for an ester.
((II) hydrogen bonded).
In the case of II there is a possibility of intramolecular
hydrogen bonding to form a six-membered ring. Therefore the
-1carbonyl absorption at 1715 cm may be due to an ester carbonyl
group of structure II which has been lowered due to hydrogen
96bonding. It is not possible on the evidence to hand to say which 
isomeric structure is appropriate for this compound, however, on 
the grounds of stability, structure ijrfs preferred.
Five small scale preparations of the compound Alclofenac-glycyl-(L) - 
histidine methyl ester, were carried out. In each case the 
chloroform insoluble fraction obtained after the work-up 
procedure was retained, bulked, and then recrystallised and 
analysed. The bulked material was found to be the required
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1The H n.m.r. spectrum, the infrared spectrum and the combustion 
analytical figures were in accord with the expected structure 
(se“e p. 72) :-
product, Alclofenac-glycyl-(L)-histidine methyl ester.
The infrared spectrum showed clear evidence for the absorptions
-1 -1associated with NH stretches at 3290cm , 3190cm and the carbonyl
— 1 - -1 -1groups absorptions at 1735cm (-CC^ .CH^ ) and at 1660cm , 1640cm
f (-C0 .NH-) . and also vinyl (CH:CH2) absorptions}*
A literature survey showed that the synthesis of histidyl peptides
97,98
has been effected by use of the azide method. The intermediate 
histidyl hydrazides have been prepared by the hydrazinolyses of 
N-blocked histidines. This procedure was followed in an attempt 
to prepare the intermediate Alclofenac-(L)-histidyl hydrazide.
The product obtained on the hydrazinolysis of Alclofenac-(L)-
histidine methyl ester was found to be insoluble in the common 
1solvents; the H n.m.r. spectrum could, therefore, not be 
obtained. The mass spectrum revealed a molecular ion at m/e377.
The infrared spectrum did not give evidence for any ester carbonyl
absorption. There was, however, clear evidence for the absorpitions
-1 -1associated with the NH stretches at 3260cm , 3160cm and a
-1carbonyl absorption at 1650cm (-C0.NH-).
The combustion analyses of this compound were in accord with the 
proposed stoichiometry, (C^H^N^C!) . (see p. 74) .
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The product was first converted to an azide by reacting it in 
suspension in ethyl acetate with nitrous acid. The azide was then 
extracted from the mixture under alkaline conditions and the dried 
organic extract was added' to a dried ethereal solution of glycine 
ethyl ester. After standing the mixture at 0°C for 24hr., the 
insoluble product which formed was filtered off. Three small scale 
preparations of this type were carried out, the products were bulked, 
recrystallised, and then analysed. The bulked material was found to 
be the required product, Alclofenac-(L)-histidyl-glycine ethyl ester.
1The H n.m.r. spectrum, the infrared spectrum and the combustion 
analytical figures were all in accord with the expected structure 
(see p. 75) :-
CH .CO.NH.CH.CO.NH.CH„.C0oC_H 2 CH 2 2 2 5
0CH2.CH:CH2
The infrared spectrum showed clear evidence for the absorptions
.  -1 associated with NH stretches at 3290cm , carbonyl absorption
-1 -1 /at 1750cm (-C02C2H,-)f and at 1650cm f(-C0-NH-).and also vinyl
(CH:CH2) absorptions^
At this stage some results of the pharmacological tests performed 
in the U.S.A. had been received. Alclofenac-(DL)-alanine methyl 
ester and Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester were 
found to inhibit the release of Histamine from the rat peritoneal 
mast cells in vitro. The free acid, Alclofenac-(DL)-alanine did 
not exhibit any bioactivity. It was then decided to prepare 
Alclofenac-(DL)-alanine amide so that a comparative study between
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1) Alclofenac-(DL)-alanine methyl ester.
2) Alclofenac-(DL)-alanine
3) Alclofenac-(DL)-alanyl amide.
The preparation of N-blocked amino acid amides has been effected
99
by use of the MCA method, aminolysis being carried out with aqueous 
ammonia. The preparation of Alclofenac-amide was carried out by 
this route.
The H m.m.r. spectrum, the infrared spectrum and the combustion 
analytical figures were in accord with the proposed structure 
(see p. .77) .
the.three forms could be made;-
The infrared spectrum showed clear evidence for the absorptions
-1 -1associated with the NH stretches at 3360cm , 3180cm and the
carbonyl group (-C0.NH-)! and also vinyl (CH:CH2) absorptions, at 
1640 cm ri
The procedure was repeated using Alclofenac-(DL)-alanine instead 
of Alclofenac itself. The product, Alclofenac-(DL)-alanine amide 
was obtained.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the proposed structure 
(see p. 79)
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•CHo.C0.NH.CH(CH_).CO.NH 
£ £  :
The infrared spectrum showed clear evidence for the absorptions
-1 -1 -1 associated with NH stretches at 3370cm , 3280cm , 3180cm and
the carbonyl absorptions (-C0.NH-) -and also-, vinyl' absorptions
-1 -1 (CH:CH2) at 1675 cm , 1625 cm
The pharmacological results of Alclofenac-(DL)-alanine amide have 
not yet been received so no comparisons can yet be made between 
1) , 2) and 3) .
Some anti-inflammatory tests were carried out at the Huntingdon 
Research Centre on Alclofenac itself and on four of the compounds 
which had already been tested in the U.S.A;
1) Alclofenac-(DL)-alanine methyl ester.
2) Alclofenac-(L)-histidine methyl ester.
3) Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester.
4) Alclofenac-glycine.
It is noted that the hydrolyses of Alclofenac-amino acid esters to 
give Alclofenac-amino acids under basic conditions do not cleave 
the peptide bond. Tests were carried out in order to determine 
whether or not Alclofenac-glycine when subjected to acidic conditions 
at pH 2-3 is hydrolysed at room temperature or at 37°C. No hydrolysis 
occurred to form Alclofenac and glycine at either temperatures under 
these conditions. Of the four compounds tested only compound 4 was 
markedly active.
Since strongly acidic or basic conditions do not cleave 
the peptide bond of Alclofenac-glyci.ne the anti-inflammatory 
activity of this derivative.could well be due to the intact 
molecule, Alclofenac-glycine.
Alclofenac has analgesic and anti-inflammatory properties, but
it possesses side effects which are believed to be due in part to
33
the unsaturated side chain. The hydrogenated form of Alclofenac,
3-chloro-4-n-propoxyphenylacetic acid, also possesses analgesic 
100
properties. It is not so active as Alclofenac itself in this
respect. We have found that Alclofenac-glycine has almost as much 
antiflammatory potency as Alclofenac itself. It was of interest
to compare anti-flammatory activity of the reduced form of this 
derivative, 3-chloro-4-n-propoxyphenylacetyl glycine with that 
of Alclofenac itself.
Hydrogenation of Alclofenac-glycine methyl ester was carried out 
in an atmospheric pressure hydrogenator. The product, 
3-chloro-4-n-propoxyphenylacetylglycine methyl ester, was a 
greasy solid of m.p. 79-82°C; it was obtained in low yield 
(~6%).
• 1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord wirth the expected structure.
    1 4 6  _  - .
(see p. 101) :-
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absorptions associated with, the NH stretch at 3260cm , carbonyl
-1 -1 absorptions at 1732cm (-C02OCH3), and at.164.0 cm (-CO.NH-)
The hydrogenation was repeated? on this occasion the product 
obtained was not isolated as a solid. The oily residue was 
saponified by treating it with an equivalent amount of sodium 
hydroxide in aqueous acetone. After a work-up procedure and 
purification the product,
3-chloro-4-n-propoxyphenylacetyl glycine, was obtained in 35%
* yield.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the expected structure 
(see p.p. 102, 103):-
The.-infrared spectrum showed • clear evidence for the presence , of
The H n.m.r. spectrum showed no indications of a signal associated 
with a CH30.C0- methyl group, the presence of a broad singlet due 
to a carboxyl group proton at 12.0ppm was observed.
The infrared spectrum showed clear evidence for
-1absorptions associated with .NH stretch at 3335cm and carbonyl
-1 -1groups at 1715cm (-C02H), and 1610cm (-C0.NH-).
The compound was obtained in approximately 32% yield by the
1hydrogenation of Alclofenac-glycine. The H n.m.r. spectrum,
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the. infrared spectrum and the ..melting point were in accord with 
those obtained previously (see p.p. 102,103).
The results of anti-inflammatory tests performed on 3-chloro-4-: 
propoxyphenylacetyl-glycine indicated that it had as much anti­
inflammatory activity as Alclofenac.
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The dipeptide phenylalany 1-phenylalanine is considered to have
16anti-inflammatory properties. Further glycyl-glycyl-(L)-histidine
t101methyl ester has been reported to be a more potent drug than 
D-Penicillamine which is itself an anti-inflammatory drug. It was 
considered to be of interest to attempt the preparation of Alclofenac 
derivatives of.these peptides.
Using the DCC method, attempts at coupling Alclofenac-glycine to 
glycine methyl ester were unsuccessful; spectroscopic investigations 
of the solid product isolated after the work-up procedure indicated 
that it was the acyldicyclohexylurea reported earlier, (see p„ 70 ); 
there was no trace of the required compound.
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El- Nagger et al have prepared glycy1-peptides by the azide method. 
It was decided to try this route in order to prepare the desired 
dipeptide derivative <> Hydrazinolysis of Alclofenac-glycine methyl 
ester was carried out in an attempt to prepare the intermediate 
hydrazide; it did not give a satisfactory product. A gelatinous 
product was obtained and, after isolation and drying, it formed a 
solid which had a wide melting range'. The infrared spectrum did 
not show any absorption associated with the ester carbonyl group.
-1It did show absorptions associated with the NH stretches at 3320cm ,
-1and the amide carbonyl group at 1645cm . No further work was 
carried out on this intractable material. (see p. 81) .
It was decided to try the coupling procedure involving the use of 
CDI. Alclofenac-glycine was activated by this agent to form an
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Alclofenac-glycyl imidazole and aminolysis was then carried out with 
the sodium salt of glycine. The product, Alclofenac-glycy1-glycine, 
was obtained.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with expected structure (see 
p.p. 82, 83)
The infrared spectrum showed clear evidence for the absorptions
-1 -1associated with NH stretches at 3330cm , 3240cm and the
-1 -ifcarbonyl absorptions at 1730cm (-C02H) and at 1650cm I (-C0.NH-) and
also vinyl (CH:CH2) absorptions^,
(L)-Phenylalanine methyl ester hydrochloride was then prepared.
1Its H n.m.r. and infrared spectra were in accord with the expected 
structure (see p. 86)
(h 3n .c h .co2.c h3)+Cl“
CH
r  l
i .(The H n.m.r. spectrum did not show the NH3 signals xn D20;
(+)these protons exchange to form N D y .
The infrared spectrum showed clear evidence for the absorptions
(+) —1 -1 —1 associated with NH3 group.at 2600cm , 2540cm , 2470cm ,
-1 -12420cm and an ester carbonyl group at 1740cm
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The melting point was. in agreement with that in the literature.
Alclofenac-(L)-phenylalanine methyl ester was prepared by both 
the ONP method and the DCC method of coupling.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures on the compound obtained by the ONP method were 
in accord with the expected structure (see p.p. 87,88).
79
O.CH2.CH:CH2
The infrared spectrum showed clear evidence for the presence of
-1absorptions associated with NH stretches at 3240cm , and carbonyl
-1 -1 (groups at 1745cm (-C02.CH3) and at 1645cm t(-CO.NH-), and also
vinyl (CH:CR2) absorptions)*
2o°c = — 6 28°The compound was optically active; it had [a]
compound was now prepared using the DCC method; for the compound 
1so prepared the H n.m.r. spectrum and the infrared spectrum were 
identical to those obtained previously (see p.p.87,88) «> No 
combustion analyses were obtained. Its specific rotation was 
measured; it had C ~ -5.29°.
The two samples had different specific rotations? a survey of the 
103literature indicates that there is a danger of some racemisation 
occurring during the coupling procedures, with more racemisation
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likely to occur in the use of DCC; the results recorded are in 
accord with this.
Alclofenac-(L)-phenylalanine methyl ester (prepared by the DCC 
method of coupling) was then hydrolysed to give the free acid, 
Alclofenac-(L)-phenylalanine
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the expected structure 
(see p.p. 90,91)
0oCH2.CH:CH2
The infrared spectrum showed clear evidence for presence of
-1absorptions associated with NH stretch at 3260cm and carbonyl 
groups and also the vinyl group absorptions (CH:CH2) at 1655 cm 1
As was discussed on p.139, racemisation is base-catalysed; some
racemisation could have occurred the reaction being carried out
under basic conditions. The product may well be a mixture of 
enantiomers.
The preparation of the compound was repeated by coupling Alclofenac 
with the sodium salt of (L)-phenylalanine using the CDI method.
The required product was obtained.
The n.m.r. spectrum, the infrared spectrum, and the melting 
point were identical to those obtained previously (see p.p. 90,91).
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The dipeptide Alclofenac-(L)-phenylalanyl-(L)-phenylalanine methyl 
ester was then prepared by, coupling Alclofenac-(L)-phenylalanine 
with (L)-phenylalanine methyl ester, using the DCC method.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the expected structure 
(see p.p. 93,94)
CH .CO.NH.CH.CO.NH.CH.CCL.CH
A  $ 2
N j / C l
0oCH2.CH:CH2
1.The H n.m.r. signal associated with the ester methyl group was 
more complex than anticipated, appearing as two singlets. As 
was explained earlier (see p.p. 128,129), this multiplicity is due 
to the fact that the product is a mixture of two diasteroisomerides.
The infrared spectrum showed clear evidence for the absorptions
-1associated with the NH stretches at 3360cm , carbonyl absorptions
-1 -1/at 1745cm (-CO^CH^)/ and at 1645cm f (-C0.NH-) and also vinyl
absorptions (CHrCHyJ,
From a literature survey it was known that one of the ways in which 
racemisation can be avoided or reduced during the DCC method of 
coupling is to lower the temperature during the coupling reaction. 
The preparation of Alclofenac-(L)-phenylalanyl-(L)-phenylalanine 
methyl ester was repeated at a lower temperature than that used 
before (-5 to 0°C). The ri n.m.r. spectrum of the product obtained 
on this occasion still showed the multiplicity seen earlier.
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Alclofenac-phenylalany1-phenylalanine methyl ester was then, 
hydrolysed.to obtain Alclofenac-phenylalany1-phenylalanine.
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the expected structure 
see p.p. 95,96):-
CH .CO.NH.CH.CO.NH.CH.CO H
O.CH2.CH:CH2
The infrared spectrum showed clear evidence for the absorptions 
associated with the NH stretches at 3240cm 1 and carbonyl
-1 ^{-CQJgroups at 1725cm (~CQ2H), and at 1625cm [(- 0.NH) and also vinyl
absorptions (CH:CH2 .^
1Since an inspection of the H n.m.r. spectrum indicated that 
racemisation was occurring even at this lower temperature of 
reaction, it was decided to work with (DL)-phenylalanine.
From it, using in each instance the DCC method, was prepared;
1) Alclofenac-(DL)-phenylalanine methyl ester.
2) Alclofenac-(DL)-phenylalanine.
3) Alclofenac-(DL)-phenylalanyl-(DL)-phenylalanine methyl ester.
4) Alclofenac-(DL)-phenylalanyl-(DL)-phenylalanine.
1All of these compounds were fully characterised. Their H n.m.r. 
and infrared spectra were all identical to those obtained for the 
corresponding compounds prepared using (L)-phenylalanine.
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Compound 4) w.as used to prepare the tripeptide derivative 
Alclofenac-(DL)-phenylalanyl-(DL)-phenylalanyl-glycine methyl ester 
by coupling it with glycine methyl ester -using the DCC method of 
coupling. The product was obtained but in a low yield (~'6%) .
1The H n.m.r. spectrum, the infrared spectrum, and the combustion 
analytical figures were in accord with the proposed structure 
(see p. 99 )
O.CH2.CH;CH2
The product was a mixture of two diasteroisomerides ; the signal 
associated with the methylene group attached to the trisubstituted 
ring appeared as two singlets as did the signal associated with the 
ester methyl group. It was not possible to make precise assign­
ments for the three NH protons, since this n.m.r. spectrum was more 
complex than those of the Alclofenac peptides prepared previously.
The infrared spectrum showed clear evidence for the presence of
-1absorptions associated with the NH stretches at 3260cm and
-1 -1 -13330cm and carbonyl groups at 1745cm (-CO^CH^) , and at 1630cm
^(-CQ.NH-) and also vinyl absorptions (CH:CH2).
All of the Alclofenac-(DL)-phenylalanyl peptides, except for this 
tripeptide derivative, were submitted for pharmacological testing. 
Alclofenac-(DL)-phenylalanyl-(DL)-phenylalanine was sent for anti­
inflammatory tests; results obtained indicated that it was less 
active than the parent compound, Alclofenac.
CONCLUSION
It has been noted in a perusal of Chemical Abstracts 89 that some 
simple peptides, derivatives of simple peptides and of amino acids 
have pharmacological activities; there is interest in this field.
Having gained some experience in working with acetylsalicylic acid, 
attempts were made to couple,, one, two, and three amino acid residues 
with Alclofenac, 4-allyloxy-3-chlorophenylacetic acid, using a 
variety of procedures. Using (DL)-alanine, glycine, (L)-histidine, 
and both (L)- and (DL)-phenylalanine, the following compounds have 
been prepared and fully characterised.
1) Acetylsalicyloyl-(DL)-alanine.
2) Alclofenac-(DL)-alanine methyl ester.
3) Alclofenac-(DL)-alanine.
4) Alclofenac-(DL)-alanine amide.
5) Alclofenac-(DL)-alanyl-(DL)-alanine methyl ester.
6) Alclofenac-glycine ethyl ester.
7) Alclofenac-glycine methyl ester.
8) Alclofenac-glycine.
9) 3-chloro-4-n-propoxyphenylacetylglycine methyl ester,
10) 3-chloro-4-n-propoxyphenylacetylglycine.
11) Alclofenac-glycy1-glycine.
12) Alclofenac-glycyl-(DL)-histidine methyl ester.
13) An acyl urea derivative which is either
a) N-(Alclofenac-glycyl)dicyclohexylurea,
or
b) 0-(Alclofenac-glycyl)dicyclohexylurea.
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14) Alclofenac-(L)-histidine, methyl ester.
15) Alclofenac-(L)-histidine hydrazide.
16) Alclofenac-(L)-histidy1-glycine ethyl ester.
17) Alclofenac-(L)-phenylalanine methyl ester.
18) Alclofenac-(L)-phenylalanine,
19) Alclofenac-(L)-phenylalanyl-(L)-phenylalanine methyl ester.
20) Alclofenac-(L)-phenylalantyl-(L)-phenylalanine.
21) Alclofenac-(DL)-phenylalanyl-(DL)-phenylalanyl glycine methyl 
ester.
Although (L)-histidine and (L)-phenylalanine were used there is
evidence, particularly in the case of Alclofenac- (L) -phenylalanyl-
(L)-phenylalanine methyl ester, to suggest that their derivatives
. lare not optically pure. An inspection of the H n.m.r. spectrum
of compound 19 shows two singlets attributed to the ester methyl
group. Further, the samples of Alclofenac-(L)-phenylalanine
methyl ester prepared by the ONP method, and by the DCC method,
had different specific rotations? the samples did not have identical
optical purity. The specific rotation of Alclofenac-(L)-histidine
methyl ester was also measured and is reported as a physical constant
for the product although it may be partly racemic. (The designation L- has
been used in the product names where the active compounds were used
in their preparation).
All compounds with the exception of 9) and 21) were prepared in 
sufficient quantities for pharmacological testing. The compounds
1) to 20) except 9) and 10) were sent to the U.S.V. Pharmaceutical 
Corporation (U.S.A.). The results to hand indicate that the compounds
2) and 5) inhibited histamine release from rat peritoneal mast cells 
in vitro.. All tests have not yet been completed, and
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Of the compounds (2,5,8, and 14) sent to the Huntingdon Research
Centre for investigation into their anti-inflammatory activity,
compound (8), Alclofenac-glycine, was found to be almost equipotent
to Alclofenac in this respect. It is not readily hydrolysed in
either acidic or basic conditions and it may be that it is a
bioactive entity in its own right rather than the hydrolysis
85product, Alclofenac. It is known that Alclofenac conjugates
with glycine in vivo when metabolised in man and monkeys. In
rodents it may be dealkylated before conjugation with glycine.
Normally such conjugates of drugs and other foreign compounds are
104pharmacologically inactive metabolites. Further, Alclofenac
33causes certain side effects which are belrved, in part, to be 
due to the presence of the allyl side chain (the hydrogenated form 
of Alclofenac 3-chloro-4-n-propoxyphenylacetic acid is somewhat
x 100less reactive than Alclofenac as an analgesic). The hydrogenated 
form of Alclofenac-glycine, 3-chloro-4-n-propoxyphenylacetylglycine, 
has been investigated for its anti-inflammatory properties ; it 
has also been found to be equipotent in this respect compared to 
Alclofenac.
Difficulties were experienced in the use of DCC when attempting to 
couple amino acid esters with Alclofenac-glycine. Although in one 
case a small quantity of the desired product was obtained, the 
major product was an acyl derivative of dicyclohexylurea. There 
are two possible isomers of this compound. It has not been 
possible to state with certainty what the structure of this 
compound is.
further results are anticipated.
The c o n c e p t t h a t  j o i n i n g  t w o .a n t i- in f la m m a t o ry  m o le c u le s  m ig ht  
p ro d u ce  a more a c t iv e  e n t it y  h a s been t e s t e d  i n  one c a se  o n ly ,  
w h ile  A lc lo f e n a c  and p h e n y la la n y 1 -p h e n y la la n in e  have a n t i ­
in fla m m a to ry  p r o p e r t ie s ,  A lc lo f e n a c - p h e n y la la n y l- p h e n y la la n in e  i s  
le s s  '^ a c t iv e  than A lc lo f e n a c .
The r e s u l t s  o f  th e  a n t i- in f la m m a t o r y  t e s t s  prom pted f u r t h e r  
p r e p a r a t io n s  and t e s t in g ;  i t  i s  hoped t h a t  when more p h a rm a c o lo g ic a l  
r e s u l t s  w ere a v a i l a b l e  t h a t  th e se  w i l l  g u id e f u r t h e r  s t u d ie s .
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I  In fo r m a t io n  r e c e iv e d  from  U .S .V . P h a rm a c e u tic a l C o rp o ra tio n ,  
(U .S .A .) on t e s t s  1 -10  (p .p .  11-18 ? code numbers as g iv e n  in  
th e U .S .V . P h a rm a c e u t ic a l C o r p o r a t io n  P r o t o c o ls ) .  Compound 
num bers r e f e r  to  the l i s t  on p . p .  1 5 6 -1 5 7 .
*
T e s t  Compound
T e s t  Code Nos
400 475 7 0 1A 702 703 704 705 706 707 708
2 R R 0 0 1 0 0 0 0 0
3 R 0 0 0 0 R 0 R 0 0
5 R 0 0 0 1 R 0 R R 0
6 R R 0 0 0 R 0 R R 0
14 R R 0 0 R R
R = T e s t  to  be p e rfo rm e d  l a t e r .
0 = Compound i s  i n a c t i v e  f o r  a p a r t i c u l a r  t e s t .
1 = Compound i s  a c t iv e  f o r  a p a r t i c u l a r  t e s t .
In fo r m a t io n  r e c e iv e d  from  .the H untingdon R e se a rch  C e n tre  on 
r e s u l t s  o f  a n t i- in f la m m a t o r y  a c t i v i t y .  Compound numb e r s  r e f e r  
to  the t e s t  on p . p .  1 5 6 -1 5 7 .
(A) T e s t  Compound A n t i- in f la m m a t o ry  a c t i v i t y
2 23.1%
5 9.9%
8 34.6%
14 0%
A lc lo f e n a c 36.0%
(B) T e s t  Compound A n t i- in f la m m a t o ry  a c t i v i t y
10 35.2%
20 13.2%
A lc lo f e n a c 35.9%
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